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Chapter 1. INTRODUCTION 
 
Summary 
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by 
the progressive development of innumerable cysts in both kidneys, which distort the 
normal kidney architecture, leading to a loss of renal function necessitating renal 
replacement therapy and/or kidney transplantation. The pathogenesis of ADPKD is 
complex, but a hallmark of the disease is enhanced renal tubular cell proliferation, 
which can be revealed in the epithelium that lines the cysts. The protein kinase 
mTOR is a central controller of cell proliferation and growth, and therefore we 
hypothesized that the mTOR signaling pathway could be dys-regulated in polycystic 
kidney disease (PKD) and treatment with mTOR inhibitors could retard disease 
progression in PKD. In a previous study, we showed that oral administration of 
rapamycin, an mTOR inhibitor, inhibited cyst growth, preserved renal functions and 
suppressed mTOR activities in the Han:SPRD rat, a rat model for PKD.   
To determine if this was a class effect of the mTOR inhibitors, we examined 
the effect of everolimus, an analogue of rapamycin, on disease progression in the 
Han:SPRD rat. We showed that a 5 week everolimus treatment by gavage feeding 
prevented the deterioration of renal function and cyst growth associated with 
decreased cell proliferation in cystic kidneys.  
Two mTOR inhibitors are currently being tested clinically in PKD patients. 
Adverse effects of mTOR inhibitors have been reported clinically that may constrain 
their potential use in PKD. Pulse treatment may increase treatment tolerability. Thus, 
we examined the effect of pulse and continuous everolimus treatment in Han:SPRD 
rats. Four-week-old heterozygous polycystic and wild-type rats were administered 
everolimus or vehicle by gavage feeding for 5 weeks, followed by 7 weeks without 
treatment, or continuously for 12 weeks. Cessation of everolimus did not allow renal 
cyst re-growth up to 7 week post-withdrawal. The partial re-activated S6 kinase and 
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recovery of cell proliferation after everolimus withdrawal may contribute to the striking 
non-cystic renal parenchyma enlargement and glomerular hypertrophy. Both 
treatment regiments ameliorated kidney function, preserved glomerular-tubular 
connection and reduced proteinuria. Pulse treatment in the early age delayed cyst 
development but led to striking glomerular and parenchymal hypertrophy which might 
have a major impact when assessing the effect of mTOR inhibitor treatment in 
patients with polycystic kidney disease. 
To explore the effects and mechanism of a wide range of everolimus levels 
(0.01 nM to 100 nM) on tubular epithelial cells, we cultured primary tubular epithelial 
cells from wild type (+/+) and Cy/+ Han:SPRD rats in 2D and 3D system. Cy/+ cells 
proliferated faster than +/+ cells as shown by a much lower population doubling time 
in Cy/+ cells. 0.1 nM everolimus reduced the cell number and DNA synthesis with no 
effect on apoptosis. Phosphorylation of mTOR, S6 kinase and S6 in Cy/+ were dose-
dependently reduced by everolimus starting from 0.1 nM in parallel with effects on 
cell number and DNA synthesis. The aggregate diameter of Cy/+ was higher 
compared to +/+ and everolimus selectively reduced the Cy/+ aggregate size. These 
data showed that an everolimus level of 0.1 nM affects cell proliferation, aggregate 
size and phosphorylation of mTOR pathway effectors.  
Taken together we revealed the critical role of mTOR in renal tubular epithelial 
cell proliferation and cyst growth in the Han:SPRD rat. Our results have substantially 
extended the knowledge of the role of mTOR inhibitors in polycystic kidney disease 
and our data may have potential clinical impacts when considering a longterm 
therapy using everolimus in ADPKD.  
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Zusammenfassung 
Die autosomal dominante polyzystische Nierenerkrankung (ADPKD) ist 
charakterisiert durch die fortschreitende Ausbildung von unzähligen Zysten in beiden 
Nieren, welche die normale Nierenarchitektur zerstört und schliesslich zu einem 
Verlust der Nierenfunktion und der Notwendigkeit für eine Nierenersatztherapie und 
Nierentransplantation führt. Die Pathogenese der ADPKD komplex ist; ein 
Hauptmerkmal ist die verstärkte Proliferation von Tubulusepithelzellen, welche die 
Zysten auskleiden. Die Proteinkinase mammalian target of rapamycin (mTOR) ist 
eine zentrale Steuerung der Zellproliferation und des Wachstums. Wir stellten 
deshalb die Hypothese auf, dass der mTOR Signalweg in polyzystischen Nieren 
dysreguliert ist und dass die pharmokologische Hemmung des Signalweges die 
Krankheitsprogression vermindert. In einer früheren Studie konnten wir zeigen, dass 
die orale Gabe von Rapamycin, ein mTOR Inhibitor, das Zystenwachstum hemmt, 
die Nierenfunktion normalisiert und die mTOR Aktivitäten unterdrückte in einem 
Tiermodell für die polyzystische Nierenerkrankung (Han:SPRD Ratte). 
Um festzustellen, ob unser Ergebnis Rapamycin spezifisch ist oder um es sich 
um eine Wirkung der Substanzklasse der mTOR Inhibitoren handeltet, untersuchten 
wir die Wirkung von Everolimus, dem Analogon von Rapamycin, auf das 
Fortschreiten der Erkrankung in der Han:SPRD Ratte. In diesem Versuch konnten 
wir zeigen, dass die Behandlung mit oral appliziertem Everolimus für 5 Wochen die 
Nierenfunktion verbessert und damit verbunden, das Zystenwachstum und die 
Zellproliferation reduziert wird.  
Zwei mTOR Inhibitoren werden derzeit klinisch in ADPKD Patienten erprobt, 
allerdings könnten mTOR Inhibitor assozierte Nebenwirkungen eine klinische 
Anwendung in ADPKD einschränken. Pulse Behandlung kann die Verträglichkeit der 
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Behandlung erhöhen. Wir untersuchten deshalb den Effekt von  Puls und 
kontinuierlicher Everolimus Behandlung in Han:SPRD Ratten. In vier Wochen alten 
heterozygote polyzystische und Wildtyp-Ratten wurden Everolimus oder das Vehikel 
während 5 Wochen über eine Magensonde appliziert, gefolgt von 7 Wochen ohne 
Behandlung oder kontinuierlich über 12 Wochen. Die Puls Everolimus Behandlung 
verhinderte ein Zystenwachstum auch 7 Wochen nach Beendigung der Therapie 
trotz einer Teilaktivierung der S6 Kinase und Zunahme der Zellproliferation. 
Auffallend waren eine nicht-zystische Zunahme des Nierenparenchyms und die 
Vergrösserung des glomerulären Volumens. Puls wie auch die kontinuierliche 
Therapie hatten die Nierenfunktion verbessert, die glomeruläre-tubuläre Verbindung 
erhalten und die Proteinurie vermindert. Eine Puls Behandlung zu Beginn der 
Erkrankung verzögert die Zystenbildung, aber führt zu einer ausgeprägten 
parenchymalen und glomerulären Hypertrophie, was die Beurteilung der Wirkung von 
mTOR Inhibitor bei Patienten mit polyzystischer Nierenerkrankung beeinflussen 
könnte.  
Um die Auswirkungen und Mechanismen einer Everolimuskonzentration von 
0,01 nM bis 100 nM auf tubuläre Epithelzellen zu untersuchen, kultivierten wir 
primäre tubuläre Epithelzellen aus dem Wildtyp (+/+) und Cy/+ Han:SPRD Ratten in 
2D- und 3D-Kultursystemen. Cy/+ Tubulusepithelzellen vermehrten sich im Vergleich 
zu +/+ Zellen schneller, dargestellt durch die wesentlich geringere 
Populationverdopplungszeit. 0.1 nM Everolimus reduzierte die Zellanzahl und die 
DNA-Synthese ohne eine Apoptose zu induzieren. Die Phosphorylierung von mTOR, 
S6 und S6 Kinase in Cy/+ wurde dosisabhängig ab einer Everolimuskonzentration 
von  0.1 nM reduziert und parallel dazu die Zellanzahl und die DNA-Synthese 
vermindert. Der Durchmesser von Cy/+ Zellaggregaten war im Vergleich zu +/+ 
Aggregaten grösser und Everolimus reduzierte selektiv den Durchmesser von 
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solchen Cy/+ Zellaggregate. Diese Daten zeigten, dass eine 
Everolimuskonzentration von 0.1 nM die Zellproliferation, die Aggregatgrösse und die 
Phosphorylierung von Effektoren des mTOR Signalwegs beeinflusst.  
Zusammenfassend haben wir die entscheidende Rolle des mTOR 
Signalweges für die tubuläre epitheliale Proliferation und Zystenwachstum in der 
Han:SPRD Ratte untersucht. Unsere Ergebnisse haben das Wissen über die 
Wirkmechanismen  von mTOR Inhibitoren bei der polyzystischen Nierenerkrankung 
wesentlich erweitert und unsere Daten haben einen Einfluss auf eine mögliche 
langfristige Anwendung von mTOR Inhibitoren in ADPKD Patienten. 
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1 Introduction 
Cystic kidney diseases are a common cause of end stage renal failure. Most 
forms of cystic kidney diseases are hereditary, but renal cysts can also be acquired 
by aging and treatments like dialysis. Onset of cystic kidney disease varies from 
newborn to seven or eight decades. Besides kidney, liver, pancreas and 
cardiovascular system are the most commonly affected. Cystic kidney diseases are 
monogenic diseases and more than 20 genes have been linked to different forms of 
cystic kidney diseases in the last 15 years. Diagnosis can be done by imaging, e.g. 
ultrasound, CT and MRI. Recently, gene sequencing has been used as molecular 
diagnosis for these diseases. Some common features of these diseases are aberrant 
proliferation, apoptosis, loss of cellular polarity, and secretion. Recently, focus has 
moved to the study of primary cilium, where most mutated genes for cystic kidney 
diseases are located.  Two-hit and third-hit hypothesis were proposed to further 
understand the mechanisms. Advances in research on these diseases in recent 
years have attributed to the availability of various new animal and cell culture models. 
At present, there is no treatment for cystic kidney diseases. However, molecular 
studies have prompted designing of clinical trials targeting several key molecular 
pathways in recent years.  In this study, we focused on mTOR, the central controller 
of cell proliferation and growth. We studied the effect of mTOR inhibition in 
Han:SPRD rat model of autosomal dominant polycystic kidney disease (ADPKD), the 
most common form of cystic kidney disease.  
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1.1 Classification of renal cystic diseases 
Cystic kidney diseases can be categorized into primary and secondary 
hereditary forms, depending on whether renal cyst is the main manifestation. Other 
cystic kidney diseases can be acquired because of non-genetic reasons like 
differentiation abnormalities and dialysis treatment. 
 
1.1.1 Autosomal dominant polycystic kidney disease (ADPKD) 
Autosomal dominant polycystic kidney disease (ADPKD) accounts for 5-10% 
of patients with end stage renal disease who require renal replacement therapy 
(dialysis or renal transplantation) 1-3. The incidence of ADPKD is between 1:400 to 
1:1000 and it affects 12.5 million people worldwide 1, 4. Although 50% ADPKD 
patients progress to end stage renal failure, the onset of clinical symptoms and renal 
function decline vary from first to eighth decades of life with an average age of onset 
in the fifth decade of life 2. Renal cysts can even be diagnosed in utero or at birth and 
2-5% of ADPKD patients present severe neonatal morbidity and mortality 5, 6. ADPKD 
is characterized by continuous growth of kidney (up to more than 10 fold) and renal 
cysts with an average annual kidney growth rate of more than 5% 4, 6, 7. Renal 
function remains stable when kidney volume increases from normal size (150-200 
cm3) in adolescence to 1,500 cm3 in the fourth or fifth decades of adulthood by when 
65% of normal renal parenchyma has been replaced by non-functional nephrons 
owing to cyst expansion and fibrosis 2, 8. The dissociation between steady cyst 
growth and the late decline of renal function can be explained by compensatory 
mechanisms (glomerular hyperfiltration) that maintain the normal renal function for 
decades. Cysts in Liver (80% patients), pancreas (10% patients), seminal vesicles, 
spleen and arachnoid membrane are often observed in ADPKD 8. Other extrarenal 
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manifestations include intracranial aneurysms, aortic aneurysms and cardiac valve 
defects. The common clinical manifestation of ADPKD include hypertension, 
hematuria, polyuria, flank pain, urinary tract infections, uric acid stones and renal 
stones (20% patients) 8. 
Macroscopically, enormous renal cysts exist bilaterally and derive from all 
segments of nephron, although only 1-5% nephrons are affected 1, 9. The size of 
renal cyst varies up to several centimetres in diameter and throughout cortex and 
medulla region.  Microscopically, the shape of cyst-lining epithelial cells range from 
columnar to cuboidal or flattened, implying the origin of renal cyst from different 
nephron segments. Cyst-lining epithelia are often surrounded by a layer of thickened 
basement membrane and a growing vasculature network 2, 7. Inflammatory infiltration 
and interstitial fibrosis caused by increased fibroblasts and collagen are observed in 
ADPKD 2, 10.  
 
1.1.2 Autosomal recessive polycystic kidney disease (ARPKD) 
The prevalence of autosomal recessive polycystic kidney disease (ARPKD) is 
approximately 1:20,000 live births 2, 4, 5. It often causes fetal and neonatal death (30% 
cases) mainly because of lung hypoplasia due to oligohydramnios. Amongst the 
survivors, 20-45% patients progress to end stage renal failure and need renal 
replacement therapy by age 15. Extrarenal manifestations include portal 
hypertension and biliary dysgenesis resulting in hepatic fibrosis. ARPKD patients in 
adolescence and adulthood present less severe renal disease, but more severe liver 
complications. 
Macroscopically, ARPKD patients develop bilateral renal cysts resulting kidney 
enlargement, but their kidneys retain reniform unlike ADPKD kidneys. The kidney 
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appears spongy, and there is no clear separation of cortex and medulla 5. ARPKD 
renal cysts mainly originate from collecting ducts presenting fusiform, ecstatic dilated 
shape and radiated from medulla to the cortex. Microscopically, a single layer of 
cuboidal epithelium lines the cysts, surrounded by abnormal deposition of 
extracellular matrix 2, 5.10-90% of collecting ducts are affected and this is associated 
with differential severity of renal disease. Unlike ADPKD, cystic lesions in ARPKD 
retain the structure of afferent and efferent connection.  
 
1.1.3 Other primary genetic renal cystic diseases  
Other primary genetic renal cystic diseases include nephronophthisis (NPHP), 
medullary cystic kidney disease (MCKD) and glomerulocystic kidney disease 2. 
NPHP cause renal failure in children or young adults. Macroscopically, NPHP 
kidneys are small and shrunken. Numerous small cysts exist in corticomedullary 
junction and they originate from distal convoluted and collecting tubules.  
Typical onset of end stage renal failure of MCKD type 1 is in sixth decades of 
life. Macroscopically, MCKD kidneys appear normal or slightly small. Numerous small 
renal cysts locate in corticomedullary junction. Average onset of end stage renal 
failure of MCKD type 2 is 32 years of age. Renal cysts are detected in inner medulla 
and probably inner medullar collecting tubule origin.  
The onset of glomerulocystic kidney disease can be early when associated 
with developmental dysplasia or later when associated with ADPKD. Glomeruli with 
dilated Bowman`s space are often detected. Glomerular tufts are often reduced or 
collapsed. 
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1.1.4 Secondary hereditary renal cystic disease 
Secondary hereditary renal cystic diseases include tuberous Sclerosis 
Complex (TSC), von Hippel-Lindau Disease (VHL), Bardet-Biedl Syndrome (BBS), 
and Oral-Facial-Digital Syndrome Type 1 (OFD-1) 2, 4. Study of secondary hereditary 
renal cystic diseases provides important insight into mechanism of cystogenesis.  
TSC is inherited as an autosomal dominant trait. Renal cysts are rarely seen 
but presented as ADPKD phenotype, probably because genes responsible for these 
two diseases are immediately adjacent in the same chromosome.  
VHL is multisystem neoplastic disorder and also inherited in an autosomal 
dominant trait. Renal cysts are seen in 70% VHL patients. VHL is characterized by 
high vascularisation due to abnormal angiogenesis.  
BBS and OFD-1 are two very rare diseases, with the the incidence 1:160,000 
and 1:50,000 live birth respectively.   
 
1.1.5 Nonhereditary renal cystic disorders 
Nonhereditary renal cystic disorders include Simple Renal Cysts, Acquired 
Cystic Kidney Disease, Multicystic Renal Disease and Medullary Sponge Kidney 2. 
These cystic diseases are caused by aging, hemodialysis, and developmental 
abanormalities.  
 
1.2 Genetics of polycystic kidney disease   
Polycystic kidney diseases (PKD) are monogenic disorders and many genes 
and encoded proteins are identified and characterized.  
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1.2.1 ADPKD genes and proteins   
ADPKD is caused by mutation in PKD1 or PKD2 genes. PKD1, localized on 
chromosome 16p13.3, accounts for 85% cases and is related to severe disease 
phenotype 4. PKD2, localized on chromosome 4q21 and accounts for the rest 15% 
cases related to less severe disease phenotype. The average onset of ESRD in 
PKD1 is 54.3 years, which is 10-20 years younger than in PKD2.  Thus, fewer 
patients with PKD2 mutation reach ESRD during their lifetime. The disease severity 
is depends on the number of cysts formed at an early age, not because of the growth 
rate of cysts 11. 
PKD1 gene, with 46 exons and 50 kb in length, encodes a transcript with open 
reading frame (ORF) of 12,909 bp. PKD2 gene, with 15 exons and 68 kb in length, 
has an ORF of 2904 bp. A large number of mutations were identified in PKD1 and 
PKD2 genes. The mutation type (either truncating or missense mutation) is not 
strongly associated with disease phenotypes, however the mutation location is 
associated with the severity of diseases 4.  Patients with mutation in 5` region of 
PKD1 developed more severe disease than in 3` region of PKD1 6.  
PKD1 and PKD2 encode polycystin 1 (PC1 or TRPP1) and polycystin 2 (PC2 
or TRPP2) respectively, which belong to the subfamily (TRPP) of transient receptor 
potential (TRP) channels. The expression of PC1 is largely reduced in adult as 
compared to fetal kidney, indicating a role transition of polycytin from tubular 
construction during development period to maturation maintenance in adult life 12, 13. 
In mouse kidney, PC1 expression peaks at embryonic (E) day 15; it falls to a low 
level two weeks after birth and this level is maintained in adult life 9. PC1 is a large 
trans-membrane protein (with 4303 amino acids and around 460 kDa) with 11 
transmembrane domains (1032 amino acids), a long extracellular domain (3074 
amino acids) and a short intracellular C-terminal region (197 amino acids). Overall 
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PC1 has a structure of a receptor or an adhesion molecule. It is a distant TRP 
homolog and may have non-selective cation channel activity by its final 6 
transmembrane domains.  Although PC1 is cleaved in the extracellular portion at the 
G protein-coupled receptor proteolytic site (GPS) domain and results in a C-terminal 
fragment (150 kDa) and N-terminal fragment, they remain tethered and the cleavage 
is important for PC1 function. C-terminal tail of PC1 contains multiple sites to interact 
with proteins to regulate cell proliferation and growth. Fluid flow inhibits the cleavage 
of C-terminal tail of PC1, which may migrate to nucleus and regulate gene 
transcriptions.  
PC1 can form a complex with E-cadherin and a,β, and γ-catenins in adherens 
juctions to regulate cell-cell interaction. In ADPKD PC1/E-cadherin complex is 
disrupted.  
PC2 (968 amino acids and around 110 kDa) is a non-selective cation channel 
with 6 transmembrane domains and contain a short N-terminal cytoplasmic region 
with a ciliary targeting motif. The cytoplasmic C-terminal of PC2 may contain a 
calcium-binding motif (EF-hand) and coiled-coil domain, which is important for 
interaction with PC2 and other TRP family members (PC1, TRPC1 and TRPV4). PC2 
can directly modulate cell cycle by interacting and sequestering transcription factor 
Id2 9.  
PC1 is proposed to function as a G protein-coupled receptor (GPCR) when 
expressed alone 9. Comexpression of PC2 with PC1 strongly suppresses the 
activation of heterotrimeric G proteins by PC1 and calcium channel activity of PC2 9, 
14. PC1/2 complex functions as a mechanosenser to sense the fluid flow. Urine flow 
shear stress may activate PC1/2 complex and subsequent lead to conformational 
change of PC1, resulting in activation of PC1 mediated G protein signaling and PC2-
mediated calcium entry.  
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Polycystins are localized in various subcellular organelles including primary 
cilium, endoplasmic reticulum, centrosome, mitotic spindles and also involved in cell-
cell and cell-matrix interactions. Subcellular transport and localization of polycystins 
can be regulated by chemical chaperones, proteasome inhibitors, phosphorylation 
and multiple interaction with adaptor proteins 6, 9, 15-17. It has been shown that 
polycystins can be packaged into exosomes and preferentially transported to primary 
cilia of kidney and biliary epithelial cells. 
 
1.2.2 ARPKD genes and proteins    
Mutation in PKHD1 (polycystic kidney and hepatic disease 1) gene causes 
ARPKD. PKHD1 (6q21) has 67 exons and is 470 kb in length and is maybe the 
largest identified disease gene up to date. It has many spliced products and with the 
longest ORF of 12,222 bp. The high level of allelic heterogeneity in PKHD1 gene is 
caused by truncating mutation (40%) or missense mutation (60%). Two truncating 
mutations always associated with the most severe cases, indicating a complete 
penetration of the mutated alleles, which produce less functional protein products. 
Animal studies have shown that PKHD1 gene is limited expressed in kidney, liver, 
pancreas and lung, whereas most PKD genes are widely expressed. The tissue 
specific expression pattern of PKHD1 gene is regulated by the transcription factor 
hepatocyte nuclear factor-1 β (HNF-1β), which bind the proximal promoter of PKHD1 
gene 5. 
Fibrocystin (4074 amino acids and 447 kDa), the protein product of PKHD1 
gene, has a large extracellular N-terminal portion (3860 amino acid), a single 
transmembrane domain and a short intracellular C-terminal tail (192 amino acids) 6. 
The proprotein convertase site in the extracellular portion of fibrocystin is thought to 
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be cleaved.  Like PC1 the C-terminal tail of fibrocystin can be cleaved and migrate to 
nucleus.  
Fibrocystin is expressed in plasma membrane, centrosomes, basal bodies, 
primary cilia and may also involve in cell-cell interactions in epithelia 5. Like PC1, 
fibrocystin can also form complex with PC2 and packaged in exosome for 
intracellular transporting. The function of fibrocystin is largely unknown, but the 
structure and localization of fibrocystin suggests a function as receptor protein 
involved in the regulation of cell adhension, repulsion, proliferation and differentiation. 
 
1.2.3 Genes and proteins for other cystic kidney diseases 
More than 20 genes and proteins responsible for other cystic kidney diseases 
have been identified and characterized. Study of these disorders provided great 
insight of the mechanism of cyst formation and development. Like PC1/2 and 
fibrocystin, these proteins mostly located in primary cilia, centrosome, and basal 
body and expressed in basal-lateral membrane for cell-cell and cell-matrix interaction. 
The most important finding in the field of PKD research is the role of primary cilium in 
cystogenesis since mutation of these genes leads to defect of primary cilium.  
 
1.3 Mechanisms of cyst genesis and development 
PKD is characterized by the expansion of fluid filled renal cysts. Initial studies 
on abnormal proliferation and secretion of cyst lining epithelia led to further 
elucidation of fundamental defects in planar cell polarity, epithelial polarity, 
proliferation, apoptosis, cell-cell interaction and cell-matrix interaction 2, 18.  
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1.3.1 Planar cell polarity   
Planar cell polarity (PCP) means the spatial organization of cells along a 
tissue plan that is perpendicular to the apical-basal axis 18. PCP proteins were initially 
found in Drosophila and consist of two pathways. The core PCP pathway involves 
the membrane proteins Frizzled, Strabismus/Van Gogh, and Flamingo/Starry Night 
and the cytoplasmic proteins Dishevelled, Prickle, and Diego. The second PCP 
pathway involves two protocadherins, Fat and Dachsous, and transmembrane 
protein called Four-jointed, and the transcriptional repressor Atrophin.  
PCP plays an important role in embryonic development by regulating cell 
migration, cell orientation, and mitotic spindle orientation, and other morphogenetic 
processes.  It has been shown for the first time by Fischer et al that abnormal PCP is 
involved in PKD. The study demonstrated that disoriented cell division led to tubular 
dilation/ cyst formation and defective PCP presented in the early stage of 
cystogenesis. Furthermore, a recent study showed that mutation of the PCP protein 
Fat4 in mice led to the disruption of orientation of cell division and subsequently 
induced polycystic kidney disease. Moreover, secreted Frizzled-related protein 4 
(sFRP4) is found to be up-regulated in human ADPKD and several different animal 
models of PKD 6. In addition, sFRP4 selectively influenced several members of Wnt 
signaling and promoted cystogenesis in zebrafish embryos. Therefore PCP 
disruption could be the key step for transformation of a renal epithelial tubule into a 
cyst. 
The aberrant PCP in PKD may be caused by defective cilium. Inactivation of 
ciliogenic gene Kif3a or Ift20 disrupted cilia formation and led to randomized 
orientation of cell division. Cilium regulate PCP may through the β-catenin 
independent non-canonical Wnt signaling pathway. Simons et al. showed that the 
protein inversin functions as a switch between canonical and non-canonical Wnt 
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signaling pathways and that fluid flow inhibits canonical Wnt signaling and thereby 
facilitate normal tubule development 19. Loss of cilium by inactivating PKD genes 
switches on β-catenin dependent canonical pathway but inhibits PCP/ non-canonical 
signaling. Cilium regulates PCP may also via Fat/Dachsous pathway. Fat4 is found to 
be localized in primary cilium and homozygous deletion of Fat4 leads to tubule 
dilation in mouse kidney 9, 20. 
 
1.3.2 Membrane polarity of epithelial cells 
Cell membrane polarity is the characteristic of cellular asymmetry at 
morphologic and functional level. Acquisition of membrane polarity is the 
fundamental hallmark of renal tubular development and maturation 2. Membrane 
polarity can be different or opposite for some proteins during development and after 
maturation. PC1 during fetal phase is primarily located at the basal membrane but 
down-regulated and restricted to apical-lateral membrane after maturation in renal 
collecting ducts.  
Loss of membrane polarity is observed in PKD. Some proteins are 
mispolarized into apical membrane. These include EGFR/Her2/neu (ErbB2) complex, 
Nak-ATPase (a1/β2 subunits), calpactin, ankyrin and fodrin. Some proteins such as 
NaK2Cl (BSC2) symporter and cathepsin L are mispolarized into basal membrane. 
Proteins like PC1, the NaK-ATPase β1 subunit, E-cadherin, and Sec6/8, accumulate 
in the cytoplasm of ADPKD cysts. However some proteins like alkaline phosphatase, 
leucine aminopeptidase and basal matrix receptors still have normal polarized 
distribution in ADPKD cystic tissue.  
The specific pattern of membrane polarization in ADPKD cysts resemble the 
pattern observed in normal fetal renal tubular epithelia. The mispolarized proteins in 
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ADPKD are caused by failure of down-regulation of fetal pattern of gene expression 
in transcriptional level. PC1 may also directly be involved in the maintenance of 
membrane polarity, since PC1 participates in the formation of cell tight junctions. 
Tight junction can prevent the membrane mispolarization owing to the movement of 
proteins in the membrane plane.  
Loss of membrane polarity in ADPKD leads to receptor, transporter and 
channel mislocalization and subsequently results in a proliferative and secretive 
phenotype. Therefore, loss of membrane polarity could be an important step after 
cystogenesis. Mutation of many other PKD genes also leads to alteration of 
membrane polarity. 
 
1.3.3 Proliferation 
Many factors contribute to the proliferative phenotype in ADPKD. 
Epidermal growth factor receptor (EGFR) is up-regulated, dispolarized into 
apical membrane and heterodimerized with Her2/neu (ErbB2), a family membrane of 
EGFR. EGF and many other EGFR ligands are in a mitogenic concentration in cyst 
fluid. It has been shown that targeting EGFR attenuated PKD progression in several 
animal models.  
The second messenger cyclic AMP (cAMP) possessess both proliferative and 
anti-proliferative capacity but it is cell type depdendent.  In the normal kidney, cAMP 
is anti-proliferative. In ADPKD and ARPKD intracellular level of cAMP is up-regulated 
and it exerts strong proliferative effects because of reduced intracellular calcium level. 
The intracellular cAMP level is regulated by hormones such as vasopressin, 
parathyroid hormone, and calcitonin on different segment of nephron.  
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High level of IL-6, IL-8, colony stimulating factor (CSF) and vascular growth 
factor (VEGF) are accumulated in cysts of long-term dialysis patients, suggesting 
they may be involved in the expansion of cysts in PKD.  
Polycystins may play a direct role in tubular cell proliferation, cell cycle and cell 
growth in PKD. The intracellular portion of PC1 interacte and sequester transcription 
factors STAT6 6.  PC2 interact with Id2, a helix-loop-helix protein in a PC1 dependent 
manner and prevent its translocation to nucleus and suppression of p21waf, a cell 
cycle inhibitor, thus preventing cyclin-dependent kinase 2 (Cdk2) activation and cell 
cycle progression. The intracellular C-terminal tail of PC1 interacts with tuberin and 
its substrate mTOR, thus suppressing protein synthesis. PC2 interacts with 
pancreatic eIF2a kinase (PERK) in endoplasmic reticulum and enhances PERK 
dependent phophorylation of transcription initiation factor eIF2a. 
 
1.3.4 Apoptosis 
Apoptosis is the programmed cell death that is characterized by reduced cell 
volume, condensed chromosome, cell surface blebbing, and DNA cleavage leading 
to apoptotic bodies. Apoptosis is important for organogenesis since cell number need 
to be tightly regulated. It has been shown apoptosis is also enhanced in ADPKD and 
ARPKD especially, in non-cystic tubules, suggesting that cyst expansion is 
accompanied by the loss of normal tubules 2. Therefore cyst formation in PKD 
resembles the process of organogenesis/tissue remodelling which needs not only a 
high rate of cell proliferation, but also a high rate of cell apoptosis. Although the 
compression of renal cysts may cause non-cystic tubular death, only 1-5% of 
nephrons are cystic in ADPKD. Therefore, it is plausible to conceive that apoptosis 
contributes to the renal failure in PKD. 
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Apoptosis has two pathways: one is intrinsic mitochondrial pathway, the other 
one is death receptor ligand mediated pathway 1. The family of cysteine proteases, 
the caspase, plays a crucial role in promotion of apoptosis in both pathways. Recent 
studies suggest both pathways are responsible for apoptosis in PKD. The mRNA of 
FasL is not up-regulated in PKD, suggesting the death receptor pathway in PKD is 
independent of death receptor ligand FasL 1. Several studies suggest TNF-α could a 
candidate ligand to stimulate apoptosis in ADPKD. It has been shown that PC1 
conveys resistance to apoptosis of renal cell lines in vitro, suggesting a direct role of 
PC1 on apoptosis in PKD.    
 
1.3.5 Secretion 
Normal kidney is a net absorptive organ to regulate the balance of fluid and 
electrolyte. Mutation in PKD genes generates a secretary phenotype in the kidney 
and theraby stimulates cyst expansion. In ADPKD, the net secretion is caused by the 
disrupted sodium gradient, increased chloride excretion and increased activity of 
water channels 2. 
In normal kidney, the low intracellular sodium level/sodium gradient is 
established by basal membrane localized NaK-ATPase. Sodium chloride enters 
apical membrane through the epithelial sodium and chloride channels. In ADPKD 
NaK-ATPase mispolarized into the apical membrane and pumping sodium and fluid 
into the cyst lumen. The mispolarization of NaK-ATPase is due to the failure of down-
regulation of the fetal β2 subunit isoform of NaK-ATPase, favouring the assembly 
a1β2 Nak-ATPase heterodimers and its trafficking to apical membrane. 
In ADPKD, chloride enters cells across basal membrane via NaK2Cl 
cotransporters, driven by sodium gradient, and exits across apical membrane via 
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cAMP-dependent chloride transporter, cystic fibrosis transmembrane conductance 
(CFTR). Increased cAMP in ADPKD stimulates CFTR, which is highly expressed and 
functional on the apical membrane of ADPKD cystic tissue. Chloride secretion in 
ADPKD can also be enhanced by ATP-mediated chloride conductance. It has been 
shown that ADPKD epithelia can excrete more ATP and the truncated PC1 promote 
ATP-mediated chloride conductance.  
Water enters cells/lumen across renal epithelial membrane via Aquaporin 
(AQP) water channels. AQP1 and AQP2 are highly expressed in ADPKD cystic 
epithelia and responsible for the fluid release. 
The mechanism of fluid secretion is different between ADPKD and ARPKD. 
Although NaK-ATPase is also mispolarized in ARPKD cysts, it is either not functional, 
or its effects are counterbalanced by the resorptive activity of other sodium 
transporters. The role of CFTR in fluid secretion in ARPKD is also not clear.  
 
1.3.6 Cell matrix interaction   
One of the most prominent phenomenons of PKD is the thickened basement 
membrane and abnormal extracellular matrix (ECM) surrounding the cysts. Abnormal 
ECM in PKD was revealed by the accumulation of structural (collagen I and III, 
laminin) and soluble ECM-associated proteins (TGF-β, βigH3, periostin) 6. The 
alteration in ADPKD basement membrane and extracellular matrix (ECM) is caused 
by the disrupted balance of matrix-degrading enzyme metalloproteinases and their 
specific inhibitors 21. In addition, ADPKD and ARPKD epithelia were found to be 
avidly adhered to basement membrane than normal renal epithelia 22. It was also 
found that ADPKD epithelia have poor migratory capacity 23.  All these suggest that 
there is a turnover defect of normal focal adhesion in ADPKD and ARPKD.  
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The high expression of fetal PC1 in punctate focal-adhesion-like bodies 
suggests a role of PC1 in the cell-matrix interaction that is necessary during early 
stage of renal development. In this early stage PC1 was required to coordinate the 
adhesion and migration of ureteric bud from underlying collagen matrix to undergo 
regulated branching morphogenesis. Many PKD proteins were found to be localized 
in focal adhesions. Disruption of components in focal adhesion complex leads to 
cystic kidney diseases. 
Some ECM components like periostin and laminin contribute to the epithelial 
cell proliferation and cyst growth 6. Periostin binds to αv-integrins, which is highly 
expressed on ADPKD cysts, and leads to accumulation of nuclear β-catenin and Akt 
activation, two factors involved in cell proliferation.  In vitro and in vivo studies 
showed that laminin-5 stimulate cell proliferation and cyst formation 6. 
 
1.3.7 Cell-cell interaction 
Early studies showed there were no abnormalities in cell-cell junction by 
showing the normal number and structure of tight junctions 2. However recent 
molecular biology studies showed that E-cadherin, the normal component of cell-cell 
junction, is replaced by fetal isoform N-cadherin, which provide a poor differentiated 
scaffold for protein interaction between β-catenin and other actin-binding proteins 24.  
Claudin-2, one of the components of tight junction in proximal tubules, is absent from 
the cysts 6. Morever over-expression of β-catenin leads to cystic kidney diseases. 
Furthermore many PKD proteins are localized in cell-cell junctions. 
The tight cell-cell junction is very important for the integrity and differentiated 
status of cells by preventing the dislocalization of polarized membrane proteins. Loss 
of differentiated status of cyst-ling epithelial cells can be observed from its 
 25 
Chapter 1. INTRODUCTION 
 
morphology. The morphology of ADPKD cyst-lining epithelia cells range from 
columnar to cuboidal to flattened, reflecting its segmental origin 2. In the late stage of 
ADPKD, increased flattened cells were detected in cyst-lining epithelia, indicating the 
loss of differentiated structure.   
 
1.3.8 Tubulointerstitium  
Besides increased ECM, the abnormalities of vasculature, fibrosis and 
inflammation were observed in PKD 2. It is not clear whether this is the secondary 
effect of maldevelopment of tubules or a direct effect of mutation of PKD genes.  
Cyst expansion could generate local pericystic hypoxia in ADPKD and further 
up-regulate the production of hypoxia-inducible transcription factors (HIFs), which is 
independent of PKD (Eckardt 2007). The extensive/abnormal vasculature detected in 
the ADPKD cyst walls could be direct result of hypoxia mediated vasculogenesis 25, 26.  
Histology studies have shown that the degree of fibrosis in ADPKD patients is 
associated with the severity of disease 27. Fibrosis can be caused by dysregulation of 
matrix proteins, peritulular capillaries and activation of fibroblasts 28. 
Hyperproliferation of fibrosis has been detected in ADPKD as a result of increased 
production of acidic-fibroblast-growth-factor 29. Some fibroblasts in PKD may be 
derived from tubular epithelial cells via epithelial-mesenchymal transformation (EMT) 
30.  
In addition to fibrosis, the degree of inflammation is also associated with the 
progress of chronic renal disease, but attracts less attention in the field of PKD. 
Increased expression of proinflammatory factors like monocyte chemoattractant 
protein-1 (MCP-1) and osteopotin were detected in the rat model of ADPKD. NFkB, 
the most important proinflammatory transcription factor, is increased in PKD-deleted 
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HEK293 cells and PKD-1 mutated cystic cells, contributing to cell proliferation and 
survival 31. The proinflammatory factor TNF-α is also overexpressed in cystic tissues 
and plays a role in cystogenesis 15. 
 
1.4 Hypothesis of cystogenesis   
1.4.1 Cilia pathology  
It is currently accepted that PKD is a disorder of primary cilia 18. Most PKD 
proteins locate in primary cilia of renal epithelial cells. Inactivation of ciliogenic genes 
like Kif3a and Ift88, leads to cystic kidney diseases.  
The primary cilium has hair-like structure and is found in most cell surfaces. It 
has a bundle of microtubules, called axoneme, surrounded by cell membrane. 
Primary cilium is anchored in basal body, which functions as centriole during mitosis. 
Assembly, maintenance and function of cilia require the movement of proteins along 
ciliary microtubules, a process called intraflagellar transport (IFT). Disruption of IFT 
genes prompted cystogenesis in animal models. Renal epithelial primary cilia 
function as mechanosensors of urine flow. Fluid flow bends primary cilia and induces 
calcium entry by mechnosensitive PC2 calcium channel 9.  
Mutation of PKD genes impairs primary cilium functions leading to disrupted 
planar cell polarity and initiate cyst formation 18. Dysfunction of primary cilia in PKD 
leads to a low intracellular calcium level, which generates a cAMP-dependent 
proliferative phenotype.  
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1.4.2 Gene dosage 
Although ADPKD is inherited as a dominant trait, it was thought be transmitted 
in a recessive fashion at molecular level. The two hit hypothesis suggests a second 
mutation in the normal allele of ADPKD leading to cystogenesis.  However it has 
been shown that induction of cyst formation does not need the complete loss of PKD 
genes.  70-80% reduction of pkhd1, pkd1 gene, leads to cyst formation 5, 32-34.  
However overexpression of pkd1 and pkd2 genes also leads to cystogenesis, 
suggesting the correct PKD gene dosage is essential for normal renal 
morphogenesis and the absence of cystic diseases 6. Recent studies showed that 
centrosomal amplification occurs in kidneys from PKD gene knocking out, over-
expressing animals and from ADPKD patients 35, 36. The link between dysregulated 
PKD genes, centrosomal amplification and genetic instability may reconcile the 
haploinsufficiency, gene dose effect, and two hit hypothesis.  
 
1.4.3 Timing of cystogensis and non-genetic factors (third hit) 
Conditional knocking out of ciliogenic or PKD genes in developing mouse 
kidneys leads to rapid development of PKD 6, 18. Inactivation of these genes in adult 
mice only causes a slower progressive cyst disease, despite of comparable loss of 
cilia. These findings suggest that the timing of cystogenesis is critical and blocking 
cystogenesis in the early time could change the course of disease progression.  
The difference between a developing kidney and mature/adult kidney is the 
high rate of proliferation and apoptosis, resembling the process that occurs during 
organogenesis and tissue remodelling upon injuries, infections and toxins 1, 18, 37. 
Indeed renal ischemia/reperfusion injuries accelerate cyst formation in adult mice 
with mutation of ciliary genes 18. In male ADPKD patients, urinary infection is 
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associated with worsening of renal function 38. Moreover, it was once demonstrated 
in a mice model that cyst formation is significantly reduced in a germ-free 
environment compared to conventional conditions. Recent studies show that up-
regulation of genes expressed in activated macrophages and complement system 
factors is associated with severe disease in cpk mouse model of ARPKD 39. In 
addition, administration of TNF-a, a potent cytokine induced in acute kidney injury or 
infections, promotes cystogenesis in adult mice with single germline mutation of 
PKD2 gene 18. A new hypothesis has been proposed with says that a third hit (non-
genetic/environmental factors) is required to initiate and accelerate cystogenesis 9. 
Indeed a nice observation in adult Pkd1 conditional knockout mouse shows that 
highly proliferating cells only present in cyst-lining and adjacent normal-looking but 
not distant epithelia, suggesting Pkd1 inactivation is not enough to initiate cell 
proliferation and a local paracrine mechanism/chemical gradient may account for 
focal cell proliferation and regional disease progression 40. Nevertheless Pkd1 
inactivation predisposes the tubular epithelial cells to a third hit, at which time the cell 
enters the cell cycle and cysts form. 
Taken together, rapid formation of renal cysts following inactivation of 
ciliogenic or PKD genes requires a high rate of proliferation and apoptosis, which is 
present in the early life of developing kidneys or in disease conditions. It has been 
shown that early onset of ESRD in ADPKD patients attributes to the number of cysts 
formed in the early ages of life instead of cyst growth rate. The high intra-familiar 
variability in ADPKD patients could be probably explained by the individual variation 
in exposure to the environmental factors in their early ages.  
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1.5 Signaling in polycystic kidney disease 
1.5.1 Mammalian target of rapamycin (mTOR) 
Structure and function 
Target of rapamcin (TOR) is a highly conserved kinase discovered from 
prokaryotes to eukaryotes 41. It actively controls energy consuming anabolic 
processes (transcription, protein synthesis, ribosome biogenesis, nutrient transport 
and mitochondrial metabolism) and negatively regulates catabolic processes (mRNA 
degradation, ubiquitin-dependent proteolysis, autophagy and apoptosis).  
mTOR is a member of the phosphoinositide 3-kinase related kinase (PIKK) 
family, whose catalytic domain has significant amino acid homology to that of the lipid 
kinase phosphoinositide 3-kinases (PI3Ks) 42. Unlike other PIKK family members, 
mTOR contain a FRB (FKBP12-rapamycin binding) domain which is required for 
FKBP12/rapamycin binding and lays immediately N-terminal to the kinase domain. 
mTOR is found in two functional and structurally distinct complexes: mTORC1 
and mTORC2 41. The defining component of mTORC1 is rapamycin-sensitive 
adaptor protein of mTOR (raptor), whereas the core unit of mTORC2 is ramapycin-
insensitive companion of mTOR (rictor). 
mTOR integrates signals from nutrients, energy and growth factors. Growth 
factors activate mTORC1 via PI3K-Akt/PKB pathway. Energy regulates mTORC1 via 
adenosine monophosphate (AMP)-dependent protein kianse (AMPK). Akt inactivates 
but AMPK activates TSC1/2 complex, which serves as a hub to integrate signals 
from energy and growth factors. TSC1/2 complex inhibits mTORC1 activity through 
suppressing small GTPase Rheb. Nutrients are the dominant TOR input. High amino 
acid level can compensate the absence of other mTORC1 inputs but not vice versa. 
Amino acids activate Rag GTPase by increasing GTP loading. The activated Rag 
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binds mTORC1 and delivers it to growth factor or low energy-activated Rheb for 
further activation of mTORC1.   
The most important substrates of mTORC1 are S6K and 4E-BP1. They both 
contain TOS motif to interact with Raptor 42. Phosphorylation of 4E-BP by mTOR 
release the it`s repression on the transcription factor eIF4B, which bind the 5`-end of 
mRNAs. Active mTOR activates eIF4B-mediated mRNA translation. mTOR also 
phosphorylates but activates another stubstrate S6K, which is originally identified as 
the kinase of ribosomal protein S6 (rpS6). However S6K stimulate cell proliferation 
and growth pathway through several other downstream targets (eIF4b, eEF2K) 
besides rpS6.  
Little is known about the uspstream regulation of mTORC2. Akt and serum 
glucocorticoid-induced kinase (SGK) are the two substrates of mTORC2 43. 
Previously mTORC2 is thought not sensitive to rapamycin, however it is found to be 
sensitive to rapamycin only in a high dose and long-time treatment 44.  
There is a negative feedback loop from S6K where S6K can phosphorylate 
and inhibit IRS/PIK/Akt pathway. 
 
mTOR signalings in PKD 
mTOR is aberrantly activated in PKD; inhibition of mTOR retards disease 
progression in animal models of PKD 1. PC1 inhibits mTOR activity probably by 
interacting with TSC2 and mTOR with its cytoplasmic tail 45. Overexpression of 
growth factors and their receptors such as IGF-1, EGF, EGFR were observed in 
animal models of PKD and human ADPKD patients 2, 46. Accumulation of these 
growth factors in the cyst kidney could stimulate Akt/mTOR pathway. Indeed Akt was 
found to be activated in Han:SPRD rat model of ADPKD 47.  
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1.5.2 Calcium/cAMP 
Calcium and adenosine 3':5'-cyclic monophosphate (cAMP) are important 
secondary messengers and implicated in cystic disease. Defection of polycystins or 
fybrocystin disrupts the cytoplasmic membrane calcium channels and reduces the 
intracellular calcium stores in PKD 48. Decreased intracellular calcium level stimulates 
calcium inhibitable adenylyl cyclise 6 and/or inhibits calcium-dependent 
phosphodiesterase 1, resulting in a high intracellular cAMP level.  The disrupted 
intracellular calcium homeostasis switches cells from cAMP-dependent anti-
proliferative to cAMP-dependent proliferative phenotype in PKD. In normal kidneys, 
cAMP inhibits the Ras/Raf-1/MEK/ERK pathway at the level of Raf-1, thus 
decreasing cell proliferation. In contrast, in conditions of calcium deprivation, cAMP 
stimulates B-Raf and activates MEK/ERK pathways in PKD, thus promoting cell 
proliferation 5.    
 
1.5.3 Tumor necrosis factor-alpha (TNF-a) 
Recent studies showed that Tumor necrosis factor-alpha (TNF-a) could be 
non-genetic factor initiating cystogenesis and accelerating disease progression 49. 
TNF-a is characterized by its ability to stimulate cell apoptosis and proliferation. In 
disease conditions such as urinary infections, renal injuries and hypertensive 
stresses, TNF-a mRNA and protein are up-regulated 49. Of note, TNF-a is up-
regulated in mouse and human PKD. Inhibition of TNF-a and TNF-a-converting 
enzyme were shown to attenuate disease progression in mouse PKD models 15, 50. 
TNF-a reduces the amount of PC2 transported to the plasma membrane and primary 
cilium via increasing the production of FIP2. FIP2 is an interacting protein which can 
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specifically interact with PC2 and prevents it trafficking to plasma membrane and 
primary cilium.  
TNF-a can stimulate proliferation via activating IKKb, which interacts with and 
suppresses the activity of TSC1/TSC2, thus activating the downstream mTOR 
pathway 51. On the other hand, TNF-a may induce apoptosis via the death receptor 
mediated pathway 2, 52. 
Taken together TNF-a may initiate cyst formation by reducing the dosage of 
PC2 in primary cilium and creating a focal microenviroment of high cell proliferation 
and apoptosis rate.  
 
1.6 Diagnosis 
Although the relative low sensitivity, ultrasound is still the most common tool to 
diagnose ADPKD due to the cost and safety reasons. The ultrasonographic criteria 
for ADPKD are based on the patient`s age, family history, and number of cysts 6, 8. 
The image resolution can be increased up to four times with magnetic resonance 
imaging (MRI) or computed tomography (CT), which can detect a minimum three 
millimetre cysts. The MRI technique is believed to be better than CT because of the 
repeated exposure of ionizing radiation to ADPKD patients during CT scan. 
Advances of molecular genetics and identification of PKD genes allows diagnosis to 
be further confirmed by DNA sequencing.  Although using current techniques can 
detect 90% of mutations, classification of these mutations as pathogenic or just 
harmless polymorphism is still difficult. For ARPKD, the large PKHD1 gene, high 
level of allelic heterogeneity and large number of spliced variants make molecular 
diagnosis very difficult.  
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1.7 Animal and cell culture models of polycystic kidney disease 
Numerous murine models phenotypically closely resemble human PKD with 
respect to cyst morphology, cyst location and disease progression. Mutation in these 
murine models can be spontaneous, chemical or genetic engineered 53.  
 
1.7.1 Rat model 
Only few rat models of PKD are available and they are all spontaneous 
mutants 53. Heterozygous cystic (Cy/+) Han:SPRD rat is a well characterized and 
extensive studied model for ADPKD. It resembles human ADPKD phenotypically and 
transmits the disease in an autosomal dominant fashion. The mutation was found in 
1989 in Hanover in a Sprague-Dawley rat strain 54. Few cystic lesions can be 
observed during the first four weeks of life in Cy/+ Han:SPRD rats and develop 
aggressively between week 4 to week 8 54. Kidney enlargement can be observed 
already during first 2-3 weeks and increases rapidly until week 8 (2 kidney weight up 
to 8 gram). Kidney size grows until week 12 and regress from week 12. It becomes 
stable between week 24 (2 kidney weight around 4.8 gram) to week 44 although still 
significantly higher than +/+ control rats. Significant azotemia develops in Cy/+ rats at 
week 8 and progresses continuous thereafter. Like human ADPKD, there is gender 
dimorphism in Cy/+ rats. Life span of male Cy/+ rats is between 10-12 months. 
Female heterozygotes have a normal life span, which is around 2 years. The 
basement thickness is observed at week 2. But significant inflammation is only 
observed until week 24. 
Cy/Cy homozygotes develop a rapidly progressive form of PKD with massive 
renal enlargement and rapid-onset of azotemia and death by week 3. Cystic changes 
involves in the whole nephron segment.  
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The limitation of this rat model is that cysts only develop in the proximal tubule 
in Cy/+ rats and they have no extrarenal manifestation, which are not similar to the 
human ADPKD.  
Mutation in Pkdr1 in chromosome 5 causes the disease in Han:SPRD rats. 
The gene Pkdr1 encodes a transmembrane protein samcystin, but its function 
remains elusive.  
The Wistar polycystic kidneys (wpk) mutant develops spontaneously in Wistar 
rat strain and is inherited in a recessive trait. Cysts are initiated at E19 in the proximal 
tubules, thick limbs, distal tubules and collecting ducts in homozygotes. Cystic 
changes progressively shift predominantly to collecting ducts and result in death at 
week 4. Wpk gene is not well characterized. Wpk rats are regarded as a ARPKD 
model, however, the biliary ductal plate malformation is not evident in this model. 
The mutation of polycystic kidneys (pck) arises spontaneously in Crj:CD/SD 
rat strain and is transmitted in a recessive fashion. Cystic lesions are observed in 
thick ascending limb of Henle, distal tubules and collecting ducts after 1 week of age 
in homozygotes. The cystic changes progress slowly and exhibit focal interstitial 
inflammation and fibrosis by 70 days of age. Biliary duct dilation is observed as early 
as 1 day of age. Male pck rats develop disease more severe than the females. Given 
the late-onset and slowly progressive PKD, the pck rats was initially regarded as a 
model of ADPKD. However it was found that the gene Pkhd1, orthologe of human 
ARPKD gene, was mutated in this rat strain. 
 
1.7.2 Mouse model 
Most mouse PKD models inherit disease in a recessive trait. Several models 
resemble ARPKD with respect to cyst pathology and disease progression. Others 
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have cysts distributed along the whole nephron, have extrarenal manifestation, 
progress slowly, and therefore are more closely approximate to human ADPKD 
phenotype.  
 
Spontaneous model 
The first described and most extensive studied mouse PKD model is 
congenital polycystic kidneys (cpk) mouse. The mutation arises spontaneously in the 
C57BL/6J (B6) mouse strain. The disease is transmitted as a recessive trait and 
phenotypically resembles ARPKD. Cystic changes are initiated at embryonic day 16 
(E16) and locate primarily in proximal tubule, but progressively shift predominantly to 
collecting ducts after birth. Death occurs by 3-4 weeks of age.  
The disease expression and severity can be modulated by genetic background. 
cpk genes locate in chromosome 12 and encodes cystin, which is localized to the 
primary cilium.  
The BALB/c polycystic kidneys (bpk) mouse and the inversion of embryonic 
turning (inv) mouse are proposed as ARPKD model, with 4 week and 1 week life 
span respectively.  
The juvenile cystic kidney (jck) mouse, the kidney, anemia, testes (kat) mice 
and polycystic kidney disease (pcy) mouse have ADPKD phenotype, with 4 months, 
2 months and 8 months of life span respectively. Of note, the gene mutated in pcy 
mouse is the orthologe of the human NPHP3 gene. Therefore pcy mouse may be a 
more appropriate model for the human NPH/MCD complex than ADPKD.  
 
Spontaneous model with immune system involvement 
There are two PKD mouse models with intensive immune system involvement, 
although the topic is presently out of focus in the field of PKD.  
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The spontaneous CFWwd mutant is inherited in autosomal dominant trait and 
displays ADPKD phenotype with respect to cyst morphology and extrarenal 
manifestations. But the penetrance of ADPKD phenotype is strongly influenced by 
environmental exposure. In the conventional facility, 100% of CFWwd mouse 
developed the disease, while only 4% of CFWwd mouse develop disease under 
germ-free conditions.  The responsible gene for CFWwd mouse was not identified.  
kd mouse is inherited as recessive trait and develops T cell-mediated 
autoimmune interstitial nephritis  and die at 5-7 months. Cystic dilation with focal 
peritubular mononuclear cell infiltration is observed in renal cortex between 10-14 
weeks of age. The kd mouse histopathologically resembles NPH/MCD disorders. The 
responsible gene for kd mouse is not identified.  
 
Chemical induced model 
The jcpk mutant was discovered in a chlorambucil mutagenesis program and 
phenotypically resembles ADPKD. Interestingly jcpk is allelic to bpk.  Probably the 
gene product of jcpk is less functional than bpk gene product. 
 
Genetic model 
A large number of PKD mouse models with null or hypomorphic alleles of pkd1 
and pkd2 orthologes have been generated 9, 53. Homozygous mutation of PKD genes 
mostly leads to embryonic death in animals. Heterozygous mutation (50% reduction 
of gene dosage) of PKD genes does not lead to cystogenesis or induces very milder 
tubular dilation. Very recently it has been shown that double mutation of pkd1 genes 
in new born mice generated a faster cystic growth phenotype. Data from these pkd1 
and pkd2 deficient mouse support two-hit hypothesis. However overepression of 
pkd1 and pkd2 genes also generate an ADPKD phenotype in mice.  
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1.7.3 Cell culture model 
With primary renal epithelial cells from ADPKD and ARPKD patients,  
Yamaguchi et al discovered the mechanism of proliferative phenotype of cAMP in 
PKD 55. Transfection of the dog renal epithelial cell line MDCK cells with pkd1 gene 
or using MDCK cells for 3D culture advanced our knowledge about the pathogenesis 
of PKD proteins 56, 57.  
 
1.8 Therapies  
Current therapy for PKD is directed towards limiting its morbidity and mortality 
from the complications of this disease 6, 8, 18. PKD patients are managed with 
supportive treatments to control pains, hypertension, and cyst infections. They are 
recommended to avoid caffeine and estrogens. Renal replacement (transplantation 
or dialysis) therapy is required for PKD patients in ESRD.  
Molecular advances in the mechanism of PKD and availability of more animal 
models facilitate designing new preclinical trials. Since the onset of cyst growth 
precedes the loss of renal function, current belief by experts in this field is that 
retardation of cyst growth will ultimately improve the loss of renal function. Several 
recent studies on PKD are underway in clinic and in animal models with drugs 
targeting signaling pathways which result in aberrant cell proliferation, apoptosis and 
fluid secretion.  
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1.8.1 mTOR inhibition   
Rapamycin (or sirolimus, the official generic name), the first discovered mTOR 
inhibitor, is a macrocyclic lactone and found in the soil bacterium Strpomyces 
hygroscopicus on Easter Island 1, 58. Everolimus is an oral 40-O-(2-hydroxyethyl) 
derivative (not prodrug) of sirolimus and has a shorter half-life as compared with 
sirolimus 58, 59. Rapamycin/everolimus inhibit mTOR activity by forming a complex 
with its intracellular receptor FKBP12 and in turn interacting with the FRB domain of 
mTOR.  
Sirolimus/everolimus was approved by Food and Drug Administration (FDS) to 
prevent graft rejection in the kidney transplant patients and inhibits tumor growth in 
cancer patients, although mild adverse effects were observed in clinical trials 1.  
mTOR inhibition by sirolimus or everolimus demonstrates promising results in 
several animal models of PKD and in transplant ADPKD patients. Sirolimus or 
everolimus retarded or even reversed cyst growth and disease progression in several 
rat and mouse models of PKD 45, 60-63. In renal transplant patients, sirolimus reduced 
the size of renal and liver cysts in renal transplant patients 45, 64. The clinical trial in 
PKD patients with everolimus trial has been initiated recently; however animal 
studies with everolimus on its efficacy and safety are still limited.    
 
1.8.2 Inhibition of other mitogeneic pathways 
Because of the importance of calcium and cAMP in PKD, targeting calcium or 
cAMP may inhibit cell proliferation and cyst growth in PKD. Increased water intake, 
vasopressin V2 receptor (VPV2R) antagonists and somatostatin inhibit cAMP-
mediated cystogenesis by reducing vasopressin level, VPV2R activity and activating 
SST2 receptor, respectively 6. Indeed a small scale clinical trial showed that 6-month 
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somatostatin therapy dccreases further the increase of cyst volume in ADPKD 
patients 65. Correcting intracellular calcium haemostasis by triptolide also reduced 
cystic burden in Pkd1 knockout mice 6.  Targeting MAPK or mTOR, downstream of 
cAMP signaling, inhibited cell proliferation and cyst development in PKD animals 6, 66. 
Inhibition of cell cycle progression by roscovitine arrested cyst growth in two mouse 
PKD models 67. Many arachidonic metabolites have mitogenic properties. Inhibition of 
these metabolites reduces cyst formation in vitro and in vivo 6.  
 
1.8.3 Inhibition of fluid secretion   
In order to inhibit fluid secretion-driven cyst expansion in PKD, transporters 
(NaK2Cl cotransporter, Na-K-ATPase, CFTR and KCa3.1) required for chloride 
secretion have been targeted. CFTR inhibiters were administered in mouse models 
of PKD, directly inhibited chloride secretion and therefore slowed cyst growth 68.  
Targeting KCa3.1 in vitro showed promising data in inhibiting chloride secretion and 
cyst formation. However targeting NaK2Cl cotransporter and Na-K-ATPase should 
be done cautiously since severe side effects can be induced 6.  
 
1.8.4 Targeting hypertension   
Hypertension occurs before and after the loss of renal function in ADPKD and 
may be attributed to the cyst compression-mediated activation of renin-angiotensin-
aldosterone system (RAAS) 69. RAAS may also play a multifactorial role in the 
pathogenesis of cyst growth by enhancing apoptosis, proliferation, fibrosis and 
production of pro-inflammatory factors. Thus, targeting RAAS by drugs like rennin 
inhibitors, ACEIs, angiotensin receptor blockers (ARBs), or adosterone antagonists 
may provide reno-protective effects in ADPKD patients.   
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1.8.5 Targeting angiogenesis, apoptosis, and inflammation   
The role of VEGF in PKD is not conclusive. Inhibition of angiogenesis by 
VEGFR inhibitors showed beneficial effects in two different animal models of PKD 70, 
71. However early inhibition of VEGFR2 during perinatal period in CD-1 mice results 
in renal cyst formation 72.  
The progression of PKD can be retarded by targeting apoptosis and 
inflammation. However the mechanism is still unknown. Inhibition of Caspase or 
specific deletion of caspase-3 can slow disease progression and prolong life in 
animal models of PKD 73, 74. Treatment with TNF-α inhibitor etanercept in Pkd2 
mutant mice reduced cyst formation via restoring the transport of PC2 to primary 
cilium. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists improved 
embryo survival and renal/extrarenal abnormalities in pkd1 knockout mice, probably 
via affecting Wnt β-catenin signalings.  
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Abstract 
The efficacy of mammalian target of rapamycin (mTOR) inhibitors is currently tested 
in patients affected by autosomal dominant polycystic kidney disease. Treatment with 
mTOR inhibitors has been associated with numerous side effects. However, the renal 
specific effect of mTOR inhibitor treatment cessation in polycystic kidney disease is 
currently unknown. Therefore we compared pulse and continuous everolimus 
treatment in Han:SPRD rats. Four-week-old male heterozygous polycystic and wild-
type rats were administered everolimus or vehicle by gavage feeding for 5 weeks, 
followed by 7 weeks without treatment, or continuously for 12 weeks. Cessation of 
everolimus did not result in the appearance of renal cysts up to 7 week post-
withdrawal despite the re-emergence of the S6 kinase activity coupled with an overall 
increase in cell proliferation. Pulse everolimus treatment resulted in a striking non-
cystic renal parenchyma enlargement and glomerular hypertrophy that was not 
associated with compromised kidney function. Both treatment regiments ameliorated 
kidney function, preserved glomerular-tubular connection and reduced proteinuria. 
Pulse treatment at an early age delays cyst development but leads to striking 
glomerular hypertrophy which might have a major impact on the treatment of patients 
with autosomal dominant polycystic kidney disease. 
 
Key words: mammalian target of rapamycin (mTOR), everolimus, polycystic kidney 
disease 
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Introduction 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
hereditary kidney disease, resulting in progressive renal failure and end stage renal 
disease in adulthood 75. The continuous growth of cysts is associated with increased 
tubular epithelial cell (TEC) proliferation leading to progressive cystic kidney 
enlargement and a loss of renal function 76.Currently specific treatments for human 
ADPKD other than supportive care do not exist.  
 
The mammalian target of rapamycin (mTOR) is a key controller of cell growth and 
proliferation 77. The pathway has two branches, which start with the mTOR 
complexes known as mTORC1, (mTOR, Raptor) and mTORC2 (mTOR, Rictor) 78. 
The former is inhibited by sirolimus (rapamycin) and its analogue everolimus, while 
the later is not. The direct downstream targets of mTORC1, ribosomal protein S6 
kinase (S6K) and 4E-BP1, in turn tightly regulate the downstream translational 
initiation machinery to control cell growth and proliferation 79. 
 
The mTOR pathway is inactive in the healthy adult kidney. In this situation tuberin, an 
upstream inhibitor of mTOR, is attached to the cytoplasmic tail of the polycystin 
complex 45. Mutations of the polycystin complex (which are the cause of ADPKD) 
direct tuberin to the cytoplasmic compartment resulting in a continuously activated 
mTOR pathway. The specific inhibition of this pathway with mTOR inhibitors can 
retard cyst growth and ameliorates kidney function loss in various murine models of 
PKD 45, 60-62, 80, 81. Based on these promising pre-clinical studies, the efficacy of 
rapamycin and everolimus, immunosuppressants approved for kidney 
transplantation, are currently examined in clinical trials for ADPKD 82, 83. Treatment 
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with mTOR inhibitors has been associated with numerous side effects, therefore 
short term or pulse treatment may offer an alternative treatment regimen to increase 
treatment tolerability. Some ADPKD patients currently enrolled in clinical trials testing 
efficacy of mTOR inhibitor treatment have been withdrawn from study drug due to 
adverse events. However, the renal specific effect of such an mTOR inhibitor 
withdrawal has so far never been examined. The purpose of the present investigation 
was therefore to study the effect of pulse compared to continuous everolimus 
treatment in Han:SPRD rats, a rodent model for polycystic kidney disease. Here we 
show for the first time, that the interruption of the mTOR treatment did not result in 
the appearance of renal cysts up to 7 weeks post-withdrawal. However, cessation of 
everolimus treatment resulted in striking glomerular and non-cystic renal hypertrophy, 
which was not associated with compromised kidney function. Pulse compared to 
continuous everolimus application differentially inhibited the mTOR pathway 
regulators AKT and GSK and the mTOR effectors rpS6 and 4E-BP1, pointing to a 
potential distinct biochemical role of mTORC1 and mTORC2 in the development and 
progression of PKD. 
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Materials and Methods 
Animals 
The Han:SPRD rat colony was established in our animal facility from a litter which 
was obtained from the Rat Resource & Research Center (Columbia, MO, USA). 
Heterozygous cystic (Cy/+) and wild type normal (+/+) rats were used in this study. 
Only male rats were used since cysts develop more rapidly in male compared with 
female rats 84. The regulatory commission for animal studies, a local government 
agency, approved the study protocol. Rats had free access to tap water and standard 
rat diet. 
 
Study drug 
Everolimus microemulsion (20 mg/g) and vehicle microemulsion were kindly supplied 
by Novartis Pharma AG (Basel, Switzerland) and stored at -20°C. Everolimus and 
vehicle were diluted with tap water before oral administration. 
 
Experimental protocol 
Male Cy/+ and +/+ rats were weaned and then treated at 4 weeks of age with 3 
mg/kg/day everolimus (Cy/+: n = 9; +/+: n = 5) or vehicle (Cy/+: n = 11; +/+: n = 8) 
(vehicle treatment [VT]) by gavage at a volume of 2 ml/kg/day for 12 weeks 
throughout (continuous treatment [CT]). In a different schedule everolimus was 
discontinued after 5 weeks, followed by 7 weeks without treatment (pulse treatment 
[PT]) (Cy/+: n = 5; +/+: n = 6). The dose of everolimus or vehicle was adjusted daily 
according to the body weight of the rats. All animals were sacrificed at week 16. 
 
Blood chemistries 
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Tail blood was obtained from rats at week 4, 8, 12 and 16. Blood urea nitrogen (BUN) 
and creatinine were determined in plasma, whereas everolimus trough levels were 
measured in whole blood. All samples were stored at –20°C prior to measurement. 
BUN was analyzed by kinetic color testing and creatinine by the IDMS traceable 
modified Jaffé method. Everolimus blood levels were analyzed by HPLC-mass 
spectroscopy. 
 
Determination of urinary protein excretion 
24-hour urine samples were collected at week 16 in metabolic cages for selected rats 
(n ≥ 4 for each group) and centrifuged. Urinary albumin was measured by a 
turbidimetric method (Roche Diagnostic, Basel Switzerland). Albuminuria was 
expressed as urinary albumin to creatinine ratios (mg/mmol). All measurements in 
blood and urine samples were performed by the Institute for Clinical Chemistry, 
University Hospital, Zurich, Switzerland.  
 
Urine was also analyzed by non-reducing SDS-PAGE. Twenty µl urine samples were 
boiled for 5 minutes at 95°C and resolved in denaturing 7.5% and 15% 
polyacrylamide gels. Electrophoresis was followed by staining of the gels with 
Coomassie brilliant blue R250 for 30 minutes. The gels were destained and washed 
in double distilled water and dried for imaging.  
 
Tissue processing 
At the age of 16 weeks, all rats were sacrificed and kidneys were excised, 
decapsulated and weighed. For histological examination, one of the kidneys from 
each animal was sliced perpendicularly to the long axis at approximately 2 mm 
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intervals. Slices from the midportion of the kidneys were fixed in 4% buffered formalin 
and submitted to subsequent paraffin embedding. Up to 65 serial sections of 3 µm 
thickness per paraffin block were cut. Every second and third consecutive slide was 
stained with regular H&E (hematoxylin eosin) and PAS (periodic- acid Schiff) stain.   
 
Morphometric measurements 
The investigators of the morphometric measurements were blinded to experimental 
groups and repeated measurements were performed without knowledge of each 
other's results.  
 
Determination of cyst volume density 
Cyst volume density (CVD) was assessed on Periodic acid-Schiff (PAS) stained 
sections by morphometry, using the method of point-counting 85. 4-6 micrographs 
were obtained for one section per rat for morphometry as described before 62. The 
pixel size of the micrographs was 1300 × 1030 (1.34 μm/pixel). An orthogonal grid 
with a line spacing of 150 pixels was used.  
 
Glomerular volume measurement 
Mean glomerular volume (GV) was determined from the mean glomerular capillary 
tuft area (AG) by light microscopy of PAS sections. The areas were determined by 
light microscopy and analyzed by a dedicated software (Analysis 3.0, Soft Imaging 
System, Münster, Germany) as the average area of 50 glomerular profiles (the 
capillary tuft omitting the proximal tubular tissue and Bowman’s capsule) for each 
animal. GV was calculated using the formula: GV = ß/k x (AG)3/2 where ß = 1.38, 
which is the shape coefficient for spheres (the idealized shape of glomeruli), and k = 
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1.1, which is a size distribution coefficient, and AG, which is the glomerular capillary 
tuft area.  
 
Assessment of glomerular-tubular connection 
Serial sections of everolimus treated and non-treated heterozygous polycystic (Cy/+) 
and wild-type normal (+/+) rat kidneys of 2 µm thickness were cut and stained with 
Periodic acid-Schiff (PAS). On the sections glomeruli were counted and each 
glomerulus examined for the presence of a urinary pole. This procedure was 
continued until 50 urinary poles were detected. If a section did not contain 50 urinary 
poles, another section of that kidney was evaluated. This section was at least 50 µm 
from the previous one to ensure that the same glomerulus was not evaluated twice. 
Sections were independently evaluated by two investigators and the results averaged. 
The number of glomeruli to obtain 50 urinary poles was used as a measure of 
glomerular-tubular connection, i.e. the higher the numbers of counted glomeruli the 
more atubular glomeruli exist in a kidney.  
 
Antibodies for immunostaining and Western blotting 
The following antibodies were used: rabbit anti-human polyclonal antibody 
recognizing Ki-67 antigen (clone MIB 1; Dako Diagnostic, Zug, Switzerland), rabbit 
anti-mTOR (7C10), mouse anti-Phospho-Akt (Ser473), rabbit anti-Phospho-GSK-
3α/β (Ser21/9), rabbit anti-Phospho-4E-BP1 (Thr37/46), rabbit anti-Phospho-S6 
Ribosomal Protein (Ser235/236), rabbit anti-Phospho-S6 Ribosomal Protein 
(Ser240/244) (Cell signaling Technology, Beverly, MA, USA), rabbit anti-actin 
(Sigma, St. Louis, MO, USA), Rabbit anti-RPS6 Antibody (Bethyl Laboratories, 
Montgomery, TX, USA), rabbit anti-Akt1/2/3 (H-136) (Santa Cruz Biotechnology, 
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Santa Cruz, CA, USA). Goat anti-rabbit HRP-conjugated antibody (Dunn 
Labortechnik GmbH, Asbach, Germany) and sheep anti-mouse HRP-conjugated 
antibody (GE Healthcare, Buckinghamshire, UK) were used as the secondary 
antibodies. 
 
Immunohistochemical detection of proliferation   
Immunhistochemistry was performed on paraffin sections of formalin-fixed tissues 
using the Ventana Benchmark automated staining system (Ventana Medical Systems, 
Tucson, AZ, USA). For antigen retrieval, the slides were heated with Ventana cell 
conditioner one (mild protocol). Anti-Ki-67 (dilution 1:20) antibody was detected with 
the Ventana iVIEW DAB detection kit, yielding a brown reaction product. Slides were 
counterstained with hematoxylin. Micrographs were made randomly using the x200 
magnification of the light microscope. The proximal tubule was identified by the brush 
border, detectable in background fluorescence and was controlled with PAS stain on 
a corresponding serial section. Nuclei of proximal epithelial cells positive for Ki-67 
were counted on 100 consecutive tubules. Tubule with less than 5 cells was not 
included for assessment. Proliferation index of TECs was calculated as the 
percentage of positively stained Ki-67 cells to total cells. The staining was scored 
independently by two observers. 
 
Protein extraction and Western blotting analysis 
Snap frozen kidney tissue was homogenized by the automated homogenizer 
(Precellys 24; Stretton Scientific, Stretton, UK) in freshly made tissue protein 
extraction reagent (T-PER, Pierce Bioscience, Rockford, IL, USA) containing 1 mM 
PMSF, 0.5 M EDTA, Halt Protease Inhibitor cocktail and Halt Phosphatase Inhibitor. 
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Homogenates were centrifuged twice at 4°C at 13,000 g for 15 min, and 
supernatants were stored at -80°C. 
 
60 µg protein samples and a reducing loading buffer were mixed and boiled for 5 min 
at 95°C. Samples were loaded on a 7.5% SDS-PAGE gel. After migration, the 
proteins of the gels were transferred onto a 0.2 µm PVDF membrane (BioRad, 
Hercules, CA, USA). The blots were blocked by drying for 15-30 min at room 
temperature and were then incubated overnight at 4°C in a 5% BSA/PBST buffer 
containing primary antibodies against actin (dilution 1:20,000), mTOR (1:1000), 
RPS6 (1:5000), p240/244 S6 (1:3000), p235/236 S6 (1:1000), Akt1/2/3 (1:1000), 
p21/9 GSK-3α/β (1:1000) or p37/464E-BP1 (1:1000). Secondary antibodies against 
rabbit (1:10,000) or mouse (1:10,000) were applied for 45 minutes at room 
temperature after 3 times wash with PBST. After 4 times wash with PBST, the 
membranes were incubated for 5 min in chemiluminescence substrate kit 
(ChemiGlow; Alpha Innotech, San Leandro, CA, USA). Blots were visualized with 
Chemi-Doc XRS system (BioRad. Richmond, CA, USA). The molecular weight of the 
bands of interest was determined by a pre-stained protein standard (SeeBlue Plus 2 
Prestained Standard, Invitrogen, Carlsbad, CA, USA). Quantification of protein 
expression was normalized to actin using densitometer and displayed as percentage 
changes over vehicle treated Cy/+. 
 
Statistical analyses 
Statistical analyses were performed by unpaired t-test or one-way ANOVA with the 
Newman-Keul’s post-hoc test using GraphPad Prism version 5.0 (Graph Pad Inc., 
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San Diego, CA, USA). All data are expressed as means ± SEM and P < 0.05 was 
considered as statistically significant. 
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Results 
In this study, everolimus was applied daily by gavage to 4 weeks old male Cy/+ and 
+/+ rats for 12 weeks (continuous treatment [CT]) or in a different schedule 
everolimus was discontinued after 5 weeks of treatment, followed by 7 weeks without 
treatment (pulse treatment [PT]). The everolimus whole blood levels were similar in 
both treatment groups at week 9 (Table 1). Judging by physical appearance, the 
treatment was well tolerated. None of the everolimus treated rats died, and all control 
rats survived. Figure 1 shows that body weight increased steadily in untreated rats 
suggesting that the cystic kidney disease by itself did not influence the normal growth 
of the animals. Everolimus treatment had an inhibitory effect on body weight gain and 
the withdrawal of everolimus at week 9 resulted in a catch-up of body weight until 
week 16.  
 
Continuous as well as pulse everolimus treatment result in cyst reduction and 
renal function preservation  
The two treatment schedules, pulse and continuous everolimus application, efficiently 
reduced cyst grow and ameliorated the kidney function in Cy/+ compared to vehicle 
treated Cy/+ (Figure 1 and 2). Pulse treatment reduced cyst volume density (-76%, 
P<0.01), lowered BUN (-47%, P<0.001) and serum creatinine levels (-47%, P<0.001). 
Likewise cyst growth (-54%, <0.01), BUN (-49%, P<0.001) and serum creatinine 
levels (-40%, P<0.001) were reduced in the everolimus continuous group. 
 
Kidney weight does not differ between pulse and vehicle treated animals due to 
significant parenchymal and glomerular hypertrophy in pulse treated animals 
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Polycystic kidney disease progression in Cy/+ led to an approximately two-fold 
increase of kidney weight and size compared to wild type rat (Figure 2A and 2B). 
Everolimus continuous treatment partly reduced this enlargement as shown by -32% 
(P< 0.001 vs. vehicle) reduced 2-kidney weight to total body weight (2K/TBW) ratio. 
In contrast, pulse and vehicle-treated Cy/+ rats had equal 2K/TBW ratios at week 16. 
This apparent absence of a kidney weight reducing effect despite retardation of cyst 
growth by pulse everolimus treatment was unexpected. We therefore assessed the 
proliferation of TEC by the quantification of Ki67 positive cells. Figure 4A shows 
representative kidney sections of all experimental groups, revealing that the 
approximately 7-fold higher proliferation rate of TECs in vehicle-treated Cy/+ 
compared to +/+ rats. mTOR inhibitors have besides its immunosuppressive effect a 
well known anti-proliferative action 86. Indeed, continuous and to a lower extent pulse 
everolimus treatment reduced the augmented proliferation of TEC and cystogensis in 
Cy/+ rats. A further histomorphological analysis revealed that the glomerular volume 
was markedly increased in pulse treated Cy/+ (77%, p < 0.01 vs. vehicle and 
continuous everolimus-treated Cy/+) (Figure 2A and 2D). A nephron deficit or the 
impairment of the glomerular-tubular connection (GTC) leads to compensatory 
enlargement of remaining glomeruli. We therefore estimated the number of nephrons 
by counting glomeruli, as a surrogate measure, and found similar values in all groups 
(data not shown). The integrity of the GTC was assessed by counting the number of 
glomeruli to identify 50 urinary poles. This number, an indicator of glomerular-tubular 
disconnection, was three-fold increased in vehicle-treated Cy/+ rats compared to +/+ 
indicating that polycystic kidneys contain large numbers of atubular glomeruli (Figure 
2E). Both everolimus regimens reduced this number in Cy/+ to the level of +/+ rats 
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demonstrating the preservation of the glomerular-tubular integrity by mTOR inhibitor 
treatment.  
 
Pulse and continuous everolimus treatment attenuated proteinuria in Cy/+ 
The enlargement of glomeruli, the development of polycystic kidney disease and 
treatment with mTOR inhibitors have been associated with increased urinary protein 
excretion 87-89. We therefore measured proteinuria, albuminuria and performed urine 
SDS-PAGE of 24h urine collection (Figure 3). Vehicle treated Cy/+ had 
approximately four-fold higher urinary total protein and albumin excretion compared 
to +/+ (Figure 3B). Both everolimus treatment schedules reduced markedly 
proteinuria. Continuous everolimus treatment reduced the urinary total protein to 
creatinine and albumin to creatinine ratio by 79% (P<0.001 vs. vehicle-treated Cy/+) 
and by 77% (p < 0.001), respectively. Pulse treatment was similar efficient and 
reduced the ratios by 48% (P<0.001) and 44% (p <0.01), respectively. Urine SDS-
PAGE revealed a strong band for albumin in samples of vehicle-treated Cy/+, a band 
that was reduced by both treatment regimens (Figure 3A). When comparing urine 
samples of Cy/+ vs. +/+ no additional differences in the band pattern were found by 
urinary SDS-PAGE (Figure 3C). These results indicate that mTOR inhibitor treatment 
reduced the augmented urinary protein excretion associated with polycystic kidney 
disease. This beneficial effect was more pronounced when everolimus was given 
continuously.  
 
Differently effect of pulse and continuous everolimus treatment regimens on 
mTOR pathway 
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Previously published in vivo studies and the enhanced understanding of polycystin 
complex disruption associated delocalization of tuberin supports the hypothesis that 
mTOR is activated in polycystic kidney disease 45. However, to the best of our 
knowledge, the expression levels of these kinases have not been previously 
assessed after mTOR treatment withdrawal. Before investigating the effect of 
everolimus treatment, we evaluated the activation of mTOR-regulated downstream 
targets (p4E-BP1 and pS6) as well as upstream regulators (pAkt) in Cy/+ kidneys. 
Phosphorylation of S6 (ser235/26 and ser240/244) and 4E-BP1, two readouts of 
mTORC1 signaling as well as p473 Akt and it`s downstream target glycogen 
synthase kinase-3 (GSK3), the readout of mTORC2 activity, were examined by 
western blot. Figure 5 shows a significant up-regulation of phosphorylated S6, 4E-
BP1 as well as Akt and GSK3 in vehicle-treated Cy/+ compared to +/+ rats, 
demonstrating constitutive activation of mTORC1 and mTORC2 in polycystic kidneys.  
 
Next, we evaluated the effect of continuous long-term mTOR inhibitor treatment on 
the mTOR complexes. Compared to vehicle treated Cy/+ rats, continuous everolimus 
treatment blocked phosphorylation of S6 whereas p4E-BP1, pAkt and pGSK3 
remained unchanged (Figure 5). These results suggest that continuous everolimus 
treatment only partly inhibited mTORC1 and that the over activated mTORC2 was 
insensitive to the mTOR inhibitor. Our findings further support a recent in vitro study 
describing such a differentially phosphorylation of S6 and 4E-BP1 after long-term 
mTOR inhibitor treatment 90.The functional consequences of a differential inhibition of 
the mTORC1 effectors along with an over active mTORC2 are not well known. In our 
PKD rat model, the continuous everolimus-mediated partial mTORC1 blockade 
reduced efficiently TEC proliferation and cyst growth without suppressing the over 
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activation of AKT/mTORC2 suggesting that mTORC2 plays a minor role in cyst 
growth.  
 
Everolimus has a short half life of approximately 12 hours and even after oral doses 
≥20 mg/wk, S6 kinase activity in peripheral-blood mononuclear cells was inhibited not 
longer than 10 days in cancer patients 91. We therefore hypothesized, that mTOR 
activity will recover after everolimus withdrawal for up to 7 weeks accompanied by a 
re-growth of cysts. Strikingly, everolimus withdrawal restored only partly the activity of 
mTORC1 whereas the signaling through Akt/mTORC2 pathway was shut down 
(Figure 5). These results indicate that recovering of kidney weight and glomerular 
enlargement in pulse treated Cy/+ can not be attributed to upregulated mTORC2 
activity and that partial active mTORC1 enabled parenchymal hypertrophy. In 
summary, components of the mTORC1 and mTORC2 are differently expressed upon 
mTOR inhibitor treatment suggesting so far unknown regulators.   
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Discussion 
The present study shows that removal of everolimus did not result in the appearance 
of renal cysts up to 7 weeks post-withdrawal despite the reactivation of the mTOR 
pathway coupled with an overall increase in cell proliferation. Cessation of 
everolimus treatment resulted in a non-cystic renal parenchymal and glomerular 
hypertrophy, which was not associated with compromised kidney function.  
 
It is generally accepted that everolimus is a global inhibitor of translation by blocking 
signaling through mTORC1 and it might be hypothesized that relief of mTOR 
inhibition would result in reactivation of the pathway and subsequent growth and 
proliferation of renal cysts. In our study it appears that prolonged everolimus 
treatment restored mTOR activity by rendering mTORC1 to be mTOR inhibitor 
resistant towards 4E-BP1 and after withdrawal towards S6 in Cy/+ kidneys. Such a 
differential regulation of mTORC1 compounds upon mTOR inhibitor application has 
been recently shown in vitro but so far not in vivo. In this in vitro long-term mTOR 
inhibitor study, p4E-BP1 remained active and mediated cap-dependent translation 
although the biological consequences of partial mTORC1 activity remains unexplored. 
In our study this partial mTORC1 activity did not mediate cyst growth and 
consequently the impact of mTORC1, in particular p4E-BP1 on cyst growth seems to 
be at least limited.  
 
Continuous mTOR inhibitor treatment markedly reduced cell proliferation and cyst 
growth whereas the aberrant activated p473 Akt/mTORC2 pathway, which plays an 
important role in cell survival and tumor growth, was not affected. Recent studies 
have shown that mTOR inhibitors have the ability to inhibit mTORC2 assembly and 
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Akt activity. However the sensitivity of mTORC2 to mTOR inhibitors is time and dose 
dependent and is further modified by the level of phosphatidic acid (PA), factors that 
may have rendered mTORC2 to become mTOR inihitor resistant in everolimus 
treated Cy/+ 78, 92. Second, rapamycin induces feedback activation of the mTOR 
upstream pathway most likely via S6 kinase and disrupted feedback loops can render 
cells to become mTOR inhibitor resistant 93-95. The inverse correlation of S6K activity 
and Akt/GSK3 in pulse and continuous everolimus treated Cy/+, suggests an intact 
negative feedback loop in kidneys of Han:SPRD rats.  
 
Our finding of a non-cystic renal hypertrophy and re-activation of the ribosomal 
protein S6 kinase which was not associated with further improved kidney function 
supports the hypothesis of a futile repair program, as proposed by Weimbs et al. 
Thus, the observed increase in cell proliferation after everolimus withdrawal may 
represent an early event preceding cyst formation 37, 96. Taken together, our findings 
confirm and extend the knowledge on the role of the mTOR pathway in cyst growth 
and suggest that at least partial mTOR/S6K activity is needed for cyst growth. 
 
Effect of everolimus treatment on glomeruli 
It is a characteristic of ADPKD that despite continuous cyst growth the glomerular 
filtration is maintained for decades due to hyperfiltration. This compensatory 
mechanism tends to increase the size of glomeruli in human ADPKD 27. In our study 
glomerular volume was similar in +/+ and continuous everolimus treated Cy/+. 
However after everolimus withdrawal, glomerular volume increased suggesting that 
the discontinuation of the mTOR inhibitor permitted the development of compensator 
hypertrophy. Indeed, the mTOR signaling pathway plays an important role in 
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glomerular hypertrophy as in several disease models activation of the mTOR 
pathway leads to glomerular hypertrophy and mTOR inhibitors prevented or retarded 
glomerular hypertrophy 97-99.  
 
Notably, this hypertrophic glomeruli were almost always connected to open proximal 
tubules pointing to the importance of an intact glomerular-tubular connection for 
adaptive processes in the glomerulus 100. The glomerular-tubular junction is 
vulnerable to toxins and stress like tubular obstruction, inflammation, ischemia and 
proteinuria, conditions that occur already early in the course of PKD 87, 101. 
Continuous and pulse everolimus treatment prevented the Cy/+ associated 
glomerular-tubular disconnection with equal efficacy probably due to the reduction of 
cyst growth and urinary protein excretion. Taken together, both everolimus treatment 
regimen preserved the glomerular-tubular connection intact whereas the 
discontinuation of everolimus permitted the development of compensatory glomerular 
hypertrophy.  
 
Our study has several limitations. First, mTOR inhibitors reduce cell size  and we 
cannot exclude that increasing cell size upon withdrawal of everolimus contributed to 
the kidney growth 102, 103. Second, the Han:SPRD rat is an imperfect model for human 
ADPKD. In the Han:SPRD rat the mutated gene encodes for samcystin and  cysts 
are mostly of proximal origin whereas in human ADPKD the genes PKD1 and PKD2 
are mutated and cysts origin from all parts of the nephron. Although, the slow 
disease progression and the gender dysmorphism resemble ADPKD phenotypically, 
the relevance of our findings for ADPKD has to be interpreted in the context of the 
animal model. Third, cyst development peaks at 8 – 10 weeks in Han:SPRD rats 
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which is followed by a development of interstitial fibrosis and decrease in renal size. 
Therefore it is possible that cyst development was equally inhibited during weeks 4 – 
9 by both treatment regimens but the discontinuation of everolimus permitted 
compensatory mechanisms. Finally we observed a significant loss of body weight in 
everolimus treated rats, which was also found in several previous similar studies 60, 80, 
81. In the absence of pair fed control groups, we cannot exclude that the body weight 
change influenced mTOR-mediated cyst growth. However, in a previous study we 
showed that a low concentration of rapamycin significantly inhibit cyst growth and 
mTOR activity independently of body weight changes 62.  
 
In conclusion, our study shows for the first time that everolimus withdrawal leads to a 
renal, non-cystic hypertrophy without the reemergence of renal cysts. In the past, 
animal studies pointed to a prominent role of the mTOR pathway in the cyst growth 
and progression of polycystic kidney disease and prompted the initiation of several 
clinical studies to examine the effectiveness of mTOR inhibitors in patients affected 
by ADPKD. Our data suggest a potential distinct biological role of the mTORC1 and 
mTORC2 pathway in cyst growth. The renal specific effect of everolimus, in particular 
after everolimus withdrawal are of considerable clinical relevance in the light of 
ongoing clinical trials testing efficacy of mTOR inhibitors in ADPKD patients. 
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 Figures legends 
 
Figure 1 
Body weight gain (A, B) of +/+ (open symbols) and Cy/+ (closed symbols) rats with 
vehicle (VT = circle), continuous everolimus (CT = square) and pulse everolimus (PT 
= triangle) treatment from week 4 to 16.  ***p < 0.001. BUN (C, D) and serum 
creatinine (E, F) levels were measured in +/+ (open symbols) and Cy/+ (closed 
symbols) rats with vehicle treatment (VT= circle), continuous everolimus treatment 
(CT = square) and pulse everolimus treatment (PT = triangle) from week 4 to 16.  **p 
< 0.01, ***p < 0.001. 
 
Figure 2 
Kidney histology was evaluated on PAS sections in +/+ (A-C) and Cy/+ (D-E) rats. 
Magnifications were x5 for the whole kidney images and x230 for the inserts. 
Representative images are shown. (G) 2-kidney to total body weight ratios (2K/TBWt) 
were measured in +/+ (open bars) and Cy/+ (filled bars) rats at week 16. (H) Cyst 
volume densities (CVD) were measured for +/+ (open bars) and Cy/+ (filled bars) rats.  
(I) Mean glomerular volume (GV) were measured for +/+ (open bars) and Cy/+ (filled 
bars) rats. (J) GT disconnection was assessed by counting glomerular number till 50 
glomeruli with urinary pole were identified. **P < 0.01, ***p < 0.001, ns: not significant. 
 
Figure 3 
(A) Proteinuria in 24-hr urine was analyzed by 7.5% SDS-PAGE (B) and quantified 
by calculating the urinary albumin to creatinine ratios in +/+ (open bars) and Cy/+ 
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(filled bars) rats. (C) Low molecular weight urinary protein was analyzed by 15% 
SDS-PAGE. **P < 0.01, ***p < 0.001.   
 
Figure 4 
Ki67 staining on +/+ and Cy/+ kidney rats. (A) Representative images are shown 
Magnifications were x200. (B) Tubular proliferation index in +/+ (open bars) and Cy/+ 
(filled bars) rats. ***p < 0.001. Representative images are shown. 
 
Figure 5 
(A) Western blot analysis of, pSer240/244 S6, pSer235/236 S6, total S6 protein, 
pThr37/46 4E-BP1 and total mTOR are shown. (B) Western blot analysis of pSer473 
Akt, total Akt and pSer21/9 GSK3 α/β are shown. Actin served as internal control. 
Quantification of protein expression was normalized to actin using densitometer and 
displayed as percentage changes over vehicle treated Cy/+ (mean values of VT Cy/+ 
were set to 1). Representative data were shown from at least three independent 
experiments. *P < 0.05, **P < 0.01, ***p < 0.001. 
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Table 
 
 
Table 1. Everolimus whole blood trough levels. 
Everolimus whole blood trough levels (µg/l ) in +/+ and Cy/+ at week 9 for continuous 
and pulse treatment and at week 16 for continuous treatment regimen. The 
everolimus whole blood levels were similar in the continuous (P=0.4) and pulse 
(P=0.7) treated animals at week 9. Mean (SEM). 
 
 
  +/+  Cy/+ 
  Continuous  Pulse  Continuous  Pulse 
week 9  4.7 ± 0.4  5.8 ± 0.4   5.8 ± 0.4  6.7 ± 0.9  
week 16  4.5 ± 0.3  _  6.2 ± 0.7  _ 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4  
 
 
0.0
2.5
5.0
7.5
10.0
Treatment       VT      CT      PT      VT      CT      PT
+/+
Cy/+


B 
Pr
ol
ife
ra
tio
n 
(%
)
 
 
 
 
Cy/+ 
+/+ 
A PT VT CT
CHAPTER 3. PULSE MTOR INHIBITOR TREATMENT EFFECTIVELY CONTROLS 
CYST GROWTH BUT LEADS TO SEVERE PARENCHYMAL AND GLOMERULA 
HYPERTROPHY IN RAT POLYCYSTIC KIDNEY DISEASE 
 
 82 
Figure 5 
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Abstract: 
 
Everolimus is currently clinically tested as treatment for autosomal dominant 
polycystic kidney disease (ADPKD) and the mechanism of action is incompletely 
explored. Previous data has shown that everolimus cause dose-dependently adverse 
events that may constrain a potential use in ADPKD. Thus, we investigated the 
effects and mechanism of a wide range of everolimus levels on tubular epithelial cells 
derived from Han:SPRD rats, an animal model for polycystic kidney disease. Primary 
2D and 3D cultures of tubular epithelial cells from wild type (+/+) and Cy/+ 
Han:SPRD rats were cultured in medium containing serum with everolimus levels 
from 0.01 nM to 100 nM. The population doubling time was 15.5±0.6h for Cy/+ and 
21.9±4.1h for +/+ TECs (p=0.012). 0.1 nM everolimus reduced cell number and DNA 
synthesis with no effect on apoptosis. Phosphorylation of mTOR, S6 kinase and S6 
in Cy/+ were dose-dependently reduced by everolimus starting from 0.1 nM in 
parallel with effect on cell number and DNA synthesis. The aggregate diameter of 
Cy/+ was higher compared to +/+ and everolimus selectively reduced the Cy/+ 
aggregate size. These data show that an everolimus level of 0.1 nM effects cell 
proliferation, aggregate size and phosphorylation of mTOR pathway effectors.  
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Introduction 
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent 
hereditary kidney disease with a prevalence between 1:400 and 1:1000 and accounts 
for 7-10% of all patients requiring renal replacement therapy 75. The relentless 
development and growth of innumerable cysts lead to progressive destruction of the 
normal renal parenchyma and massive enlargement of the kidneys 62, 63, 104. Currently 
there is no specific treatment for ADPKD other than supportive care, and dialytic 
treatment or renal transplantation when patients have reached end stage renal 
disease. 
 
Several molecular mechanisms contributing to cyst formation have been proposed, 
including altered intracellular signaling leading to a dysbalance in epithelial cell 
proliferation and apoptosis. The mTOR (mammalian target of rapamycin), an atypical 
serine/theronine kinase plays a central role in modulating cellular proliferation, and 
apoptosis 105. This pathway is aberrantly activated in polycystic kidneys of different 
rodent models for ADPKD, as well as in cyst-lining cells in human ADPKD 45, 62, 81. 
Everolimus (Certican®) and sirolimus (Rapamune®) are two specific and potent 
mTOR inhibitors that efficiently slow disease progression in the Cy/+ rat, a rodents 
models for polycystic kidney disease (PKD). Thus, key features of PKD are tubular 
cell proliferation, suggesting that mTOR inhibitors act via its anti-proliferative, and 
pro-apoptotic action. 
 
Everolimus and sirolimus are currently clinically tested as treatment for ADPKD 
patients [NCT00346918 and NCT00414440]. However, mTOR inhibitors cause dose-
dependently adverse events that may constrain a potential long-term use in ADPKD. 
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Dose-finding studies in ADPKD patients are planed but will last years and involve a 
large number of patients as the disease progresses slowly. Because of these 
potential detrimental effects, we aimed to determined the renal tubular epithelial cell-
drug concentration relationship for everolimus in vitro to define the lowest inhibitory 
dose of everolimus of Cy/+ tubular epithelial cells proliferation.  
 
We studied the effect of everolimus in primary 2D and 3D cultures of renal tubular 
epithelial cells from male Cy/+ rat and provide a number of novel findings. The 
augmented cell proliferation was inhibited by a remarkable low dose of everolimus in 
parallel with a dose-dependent specific inhibition of mTOR pathway with no effect on 
apoptosis. The aggregate diameter of Cy/+ was higher compared to +/+ and 
everolimus selectively reduced the Cy/+ aggregate size. 
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Materials and methods 
Renal tubular epithelial cell isolation 
The Han:SPRD rat colony was established in our animal facility from a litter which 
was obtained from the Rat Resource & Research Center (Columbia, MO, USA) and 
kept under local regulation and guidelines. Heterozygous cystic (Cy/+) and wild-type 
normal (+/+) male rats, aged 2-4 months were used in this study. Primary renal 
epithelial cells were isolated as follows. Kidneys were minced and digested by 1 
mg/ml collagenase with gentle agitation for 1 hour at 37°C. Suspension was allowed 
to sediment 1 minute twice. Cells were collected by harvesting the supernatant and 
then washed 3 times with 10% FBS/HBSS.  
 
Monolayer cell culture 
Isolated cells were re-suspended in K1 medium (1:1 mixture of Dulbecco's modified 
Eagle's medium (Invitrogen ) and Ham's F-12 medium (Invitrogen ) supplemented 
with 5% FBS (Invitrogen ), 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
(HEPES; Invitrogen) (pH 7.4), 42 mM sodium bicarbonate (Sigma), 5 g/ml insulin 
(Sigma), 50 nM hydrocortisone (Sigma), 5 g/ml transferring (Sigma), 5 pM 
triiodothyronine (Sigma), 100 IU/ml penicillin (Invitrogen), and 100 g/ml streptomycin 
(Invitrogen)) and incubate at 37°C, 95% O2, 5% CO2 on 10 μg/ml collagen (Sigma) 
coated 100 mm Falcon plastic petri dishes or 96-well plates for indicated experiments. 
The percentage of successful plated TEC was different for Cy/+ and +/+ (13% vs. 
1.1%). Thus to reach the same degree of cell confluence at day 1, isolated TECs 
from +/+ or Cy/+ rats were seeded at 5-10 x 106 or 5-10 x 105 cells/ml, respectively. 
At following day (day 1), TECs reached 10-20% confluence and were washed 2 times 
with HBSS and replaced with fresh K1 medium in the absence or in the presence of 
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20 ng/ml rat epidermal growth factor (EGF; R&D). Positive staining for epithelial 
marker cytokeratin and negative staining for CD31 were obtained to characterize 
tubular epithelial cells (TECs).  
 
Study drug 
Everolimus as dry powder was kindly supplied by Novartis (Basel, Switzerland) for in 
vitro study. The powder was dissolved in ethanol and stored as 10 mmol/L stock 
solution at – 20°C.  
 
Total protein assay 
TECs from +/+ or Cy/+ rats were cultured in 100 mm Falcon plastic petri dishes in the 
presence of various concentrations (0.01nM to 100nM) of everolimus, rat epidermal 
growth hormone (EGF), minimal medium (K1 medium supplemented with 0.02% FBS, 
in the absence of growth hormones) or in normal K1 medium from day 1 for indicated 
experiments. Cell lysates were prepared by scraping cells from dishes using protein 
extraction reagent (T-PER, Pierce Bioscience, Rockford, IL, USA) containing 1 mM 
PMSF, 0.5 M EDTA, Halt Protease Inhibitor cocktail and Halt Phosphatase Inhibitor). 
Total protein content of lysates was measured using BCA assay (Pierce Bioscience, 
Rockford, IL, USA) according to the manufacturer's instructions.  
 
Colorimetric cell number assay   
TECs from +/+ or Cy/+ rats were cultured in 96-well plate in the presence of various 
concentrations (0.01nM to 100nM) of everolimus or in normal K1 medium from day 1 
for indicated experiments. The number of viable cells was determined by MTS assay 
using the CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega, 
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Madison, WI, USA) according to manufacturer’s instructions. The absorbance was 
read at 492 nm with a microplate reader (Labsystems Multiskan RC., Haverhill, MA, 
USA). 
 
BrdU uptake proliferation assay 
Alternatively, cell proliferation was assessed using BrdU Cell Proliferation ELISA Kit 
(Cat. No. 1 647 229, Roche Applied Science, Basel, Switzerland), which quantifies 
cell proliferation by measuring DNA synthesis. Assay was performed according to 
manufacturer’s instructions and results were expressed as mean absorbance of the 
samples in an ELISA plate reader (Molecular Devices Uvmax Reader) at 450 nm with 
a reference wavelength of 690 nm.  
 
Apoptosis Assays 
We determined apoptosis by 3 different methods. First, western blots (detail 
described in Western blot analysis) were performed to analyze the expression of 
caspase-3, a well characterized apoptosis marker.   
 
Second, apoptosis was quantified by analyzing FACS for annexin V. Cell cultures of 
Cy/+ TECs were harvested by trypnization and double-stained with propidium iodide 
(PI) and fluorescein isothiocyanate-conjugated annexin V (Sigma, St. Louis) at day 3. 
Flow cytometry was performed with FACScan (Becton Dickinson) and the results 
were analyzed with the FACScan cellquest software Cells PI–/Annexin V+ were 
defined as early apoptotic cells, PI+/Annexin V+ as late apoptotic, and PI+/Annexin V– 
as dead cells. H2O2 treated TECs served as positive controls.  
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Third, the APOPercentage Apoptosis Assay (Biocolor, Belfast, Northern Ireland) was 
used to quantify apoptosis.106 This assay discriminate apoptotic cells from necrotic 
cells as apoptotic cells undergo the membrane “flip-flop” event when 
phosphatidylserine is translocated to the outer leaflet. Cultures of Cy/+ were gently 
washed twice with PBS and medium were replaced by 100 μL apopercentage dye 
and incubatedat 37°C at day 3. After 1h, the cells were again washed twice with 100 
μL PBS to remove un-trapped dye and 100 μl/well apopercentage dye release 
reagent was added for 10 min. The absorbance of the cell bound dye recovered in 
solution was measured using a microtitre plate colorimeter reader at 550 nm 
(maximum dye absorbance) and 625 nm (minimum dye absorbance). TECs 
incubated with 1mM H2O2 for 1h were served as positive controls.  
 
Western blot analysis   
Western blot was done by standard methods. Briefly, 10 to 20 µg proteins extracted 
from cultured cells were boiled for 5 minutes, resolved in non-reducing SDS/PAGE 
and then subjected to Western blot analysis. The following antibodies were used: 
rabbit anti-phospho-mTOR (Ser2448), rabbit anti-phospho-mTOR (Ser2481), rabbit 
anti-phospho-p70 S6 kinase (Thr389), rabbit anti-phospho-p70 S6 kinase 
(Thr421/Ser424), rabbit anti-Phospho-S6 Ribosomal Protein (Ser235/236) (Cell 
signaling Technology, Beverly, MA, USA), rabbit anti-caspase-3 (Cell signaling 
Technology, Beverly, MA, USA), and rabbit anti-actin (Sigma, St. Louis, MO, USA).  
 
Aggregates formation and quantification 
At day 1, TECs from Cy/+ and +/+ rats were harvested and seeded at 1 x 105 cells/ml 
into 6-well plates pre-coated with 1% tissue culture grade agar. Various 
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concentrations of everolimus (from 1 nM up to 100 nM in DMSO) or equivalent 
amount of solvent were added into the cell culture at the moment of plating on agar. 
At day 3, cell aggregates were formed and immobilized by embedding into collagen 
(2 g/l collagen type I solution (Vitrogen 100), 20mM HEPES (pH 7.4), 25mM 
NaHCO3) at 37°C for 1 h. Cell aggregates were fixed for 30 min with 4% FA/PBS at 
37°C. Fluorescein-phalloidin (10 μg/ml in PBS) was applied for 1 hour at RT to stain 
F-actin outlining individual cells. Hoechst (10 µg/ml in PBS) was used to stain nuclei 
for 5 min at RT. Gels were mounted in mowiol/DABCO. Confocal images of 
aggregates were taken using Leica SP2 microscope equipped with an oil-immersion 
objective (40x, 1.3 NA, Leica Microsystems). Aggregate size was quantified using 
LSM Image Browser software (Zeiss).  
 
Statistical analyses 
Cell population doubling time was calculated by plotting cellular growth or 
proliferation against time. The everolimus concentration required to inhibit cell growth 
by 50% (IC50) was calculated by interpolation of dose-response curves using 
GraphPad Prism 4 software. Statistical analyses were performed by one-way 
ANOVA with the Newman-Keul’s post-hoc test. All data are expressed as means ± 
SEM and P<0.05 was considered as statistically significant.  
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Results 
Tubular epithelial cells form Cy/+, compared to +/+, have a lower cell population 
doubling time in monolayer cultures 
To investigate the proliferation capacity of +/+ and Cy/+ TECs, we determined the 
time of cell population doubling in monolayer cultures in the presence of absence of 
growth hormones. Total protein measurement and a colorimetric method gave similar 
results. Figure 1 shows that, with cell number assessed by colorimetric assay, the 
doubling time was significant lower of Cy/+ compared to +/+ in the absence of EGF 
(Cy/+ 15.5±0.6h vs. +/+ 21.9±4.1h, p < 0.05). Addition of EGF to the cell medium 
from day 1 to day 3 decreased the doubling time in both cell types, however Cy/+ still 
significantly proliferated faster than +/+, suggesting a preserved proliferation capacity 
despite basal high proliferation rate in Cy/+ TECs (data not shown).  
 
Everolimus inhibited in dose-dependent manner and increase in Cy/+ tubular 
epithelial cell number by inhibition of proliferation 
To explore the effects of everolimus on Cy/+ TECs, we assessed the cell number by 
colorimetric assay in the presence of varying concentration of everolimus (0.01 nM to 
100 nM). Figure 2A shows that, exposure of Cy/+ TECs to everolimus for 2 days 
resulted in a dose-dependent decrease of cell number (IC50 0.07±0.08 nM), starting 
from a concentration as low as 0.1 nM (0.1 nM vs 0 nM, p < 0.05; 0.01nM vs 0nM > 
0.05) with no additional effect at higher everolimus concentration (0.1 nM vs 100 nM, 
p > 0.05) To assess whether the effect of everolimus on cell number that we had 
observed by the colorimetric assay was due to inhibition of proliferation, we used a 
BrdU uptake assay. Cells were cultured in the presence of varying doses of 
everolimus and BrdU was added at day 3. As shown in Figure 2B the effect on 
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proliferation mirrored that which we had seen on the colorimetric cell number assay. 
Everolimus showed a clear dose-dependent effect on DNA synthesis of Cy/+ tubular 
epithelial cells, starting to reduce cell proliferation at dose of 0.1 nM everolimus (0.1 
nM vs 0 nM, p < 0.05; 0.01nM vs 0nM > 0.05; 0.1 nM vs 100 nM, p > 0.05). The 
proliferation inhibitory concentration of everolimus determined by BrdU uptake (IC50 
0.07±0.08) was similar to the IC50 assessed by colorimetric assay, indicating that the 
effect of everolimus on cell number was due to the direct inhibition on cell 
proliferation. 
 
Everolimus did not reduce cell number by apoptosis 
A possible explanation for the anti-proliferative effect of everolimus on tubular 
epithelial cells was that everolimus caused an increase in apoptosis, as this had 
been described for other cell types . Caspase 3, the convergence point of intrinsic 
and extrinsic apoptotic pathways, is a well-characterized readout for the presence of 
apoptosis. We therefore determined the expressions of caspase-3 by Western Blot 
and compared to untreated Cy/+ tubular epithelial cells, everolimus up to a 
concentration of 100 nM did not increase the expressions of proform (32KD) and 
activative form (17 kD) of caspase-3 (Figure 3A). Apoptosis is characterized by 
morphologic changes resulting in the exposure of phasphatidylserine on the outer 
membrane surface, which can be recognized by anti-Annexin V antibody. FACS 
analysis with anti-Annexin V antibody and no-vital dye propidium iodide (PI) 
discriminate viable (Annexin-PI-), early apoptotic (Annexin+PI-) and late apoptotic or 
necrotic cells (Annexin+PI+). Figure 3B shows that everolimus did not increase early 
or late apoptotic/necrotic cells in any concentrations. The number of Annexin+PI+ and 
Annexin+PI- cells in control and everolimus treated samples could be due to the 
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damage incurred during trypsinization procedure, which could mask a possible effect 
of everolimus on cell apoptosis. Thererfore, we measured apoptosis using the 
apopercentage assay, which detects membrane alterations (phosphatidylserine flip) 
without prior trypsinization. Figure 3C shows that only few cells are stained positive 
for apoptotic cells in the presence of everolimus. Quantification of apoptotic cells by 
the apopercentage assay confirms that everolimus up to a concentration of 100 nM 
did not increase the number of apoptotic Cy/+ tubular epithelial cells (Figure 3D). 
Taken together, these results of 3 independent methods to detect apoptosis showed 
that the effect of everolimus on cell number was not due to increased apoptosis. 
 
Everolimus dose-dependently decreased phosphorylation of mTOR and its 
downstream effectors S6 kinase and S6 
To elucidate molecular mechanisms of everolimus induced inhibition of cell 
proliferation we determined the expression of mTOR pathway targets by western 
blots Figure 4A shows that two phosphorylation sites of mTOR were dose-
dependently reduced by everolimus in Cy/+ tubular epithelial cells. Reduced 
expression of p2481 mTOR was evident at an everolimus concentration of 0.1 nM. A 
higher everolimus concentration further reduced p2481 mTOR expression reaching a 
nadir at 1 nM. A reduction of p2448 mTOR expression was seen at an everolimus 
concentration of 1nM and showed no further inhibition with higher concentration. 
Figure 4B shows everolimus inhibited the phosphorylation of S6 kinase, a direct 
downstream target of mTOR. The expression of p389 S6K and p421/424 S6K were 
dose-dependently reduced by everolimus, starting from a concentration as low than 
0.1 nM. Dose-dependent decreased S6K activity was further confirmed by western 
blot analysis of p235/236 S6, a direct substrate of S6 kinase. These results show a 
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dose-dependant effect of everolimus on mTOR, S6 kinase and S6 phosphorylation in 
Cy/+ tubular epithelial cells and demonstrate these effects at same dose range that 
inhibited proliferation. 
 
Everolimus reverted the increased diameter of Cy/+ tubular epithelial cell aggregate 
to the size of +/+ 
To study whether everolimus affects cyst formation in vitro, we cultured primary Cy/+ 
and +/+ tubular epithelial cells in suspension system with the aim to generate a 3D 
cell culture model for cystogenesis. Cy/+ and +/+ tubular epithelial cells formed 
aggregates 48 hours after plating. Figure 5A and C showed that the diameter of 
tubular epithelial cell aggregates originated from Cy/+ compared to +/+ was 
significantly higher (50±2 μm vs. 33±1 μm p < 0.0001). However the increase in 
aggregate size could not be attributed to appearance of luminal space inside the 
aggregates as confocal imaging demonstrated that there was no lumen in the 
absolute majority of either Cy/+ or +/+ aggregates (Figure 5B). The concentration of 
Cy/+ aggregates was lower than of +/+ (159±30 vs. 260±35 aggregates per 1 mm3, 
respectively) suggesting that some of the larger aggregates might have been formed 
by aggregate fusion. Both 1nM and 100 nM Everolimus significantly reduced the 
diameter of Cy/+ aggregates from 50±2 μm to 34±1 μm and 36±2 μm (p < 0.0001), 
respectively, to the range of +/+ aggregates. The diameter of +/+ aggregates 
remained unchanged by everolimus at a dose range of 1-100 nM (p = 0.298 and p = 
0.232; Figure 5C and D). These results suggest that everolimus selectively inhibits 
either formation or growth or both of these parameters of Cy/+ tubular epithelial cell 
aggregates. 
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Discussions 
Our study demonstrated that 0.1 nM was the lowest concentration of everolimus that 
affected cell number and DNA synthesis with no effect on apoptosis. The inhibition of 
cell proliferation was tightly linked to the reduced phosphorylation of mTOR, S6K and 
S6. In a 3D culture system, everolimus reduced the size of Cy/+ aggregates, the first 
step of cyst/lumen formation.  
 
In our in vitro culture system, the doubling time of Cy/+ TECs was significantly lower 
than +/+ TECs, which was in line with the in vivo finding that the proliferation index in 
the kidney was higher in Cy/+ than +/+ 63, 81. The everolimus dose inhibiting S6K 
activity was remarkable low (0.1 nM) in Cy/+ tubular epithelial cells. The sensitivity of 
cells to everolimus or rapamycin shows large variation in different cell types or 
species. 0.1 ng/ml (approximately equal to 0.1 nM) rapamycin in mouse mesangial 
cells 107, 0.5 nM and 20 nM rapamycin in human breast cancer cell MCF-7 and MDA-
MB-231, respectively, decreased S6K activity 108. Interestingly, in our study S6K 
activity was tightly linked to cell proliferation. A similar finding was reported by Lock 
et al. in mouse mesangial cells, suggesting a dominant role of the mTOR/S6K 
pathway in both cell types 107. The level of rapamycin (0.5 nM for MCF-7 and 20 nM 
for MDA-MB-231), which inhibited S6K phosphorylation in MCF-7 and MDA-MB-231 
cancer cells did not inhibit cell proliferation  92, 108. The reason for this apparent 
difference in the anti-proliferative effects is due to the activation of multiple mitogenic 
pathways such as p27 and/or c-Myc, which confer resistance to rapamycin 1, 109, 110.  
 
Currently blood level of everolimus or rapamycin achieved in most animal studies 
and clinical trials is between 4.5-14 nM (ng/ml) 60, 92, 107. In our previous in vivo study, 
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we achieved blood trough levels of 5-7 nM by daily administration of everolimus 
(3mg/kg) using gavage 63. In the current study a 0.1 nM everolimus level efficiently 
inhibited cell proliferation in vitro, which was in line with our previous in vivo study in 
which 0.5 nM blood rapamycin levels retarded cyst growth in Cy/+ rats 62. Similarly, 
low everolimus dose (0.3 mg/kg) exerted a significant anti-proliferative effect on 
mesangial cells in a rat model of glomerulonephritis, which confirms the previous 
finding by Lock et al that 0.1 nM rapamycin in vitro inhibited renal mesangial cell 
proliferation 111.  
 
Apoptosis is increased in polycystic kidneys and occurs in a similar rate in both cystic 
and non-cystic tubules 2, 73. In a previous study in Cy/+ rats, TUNEL staining showed 
apoptosis in most cells of a particular tubule section whereas other tubules showed 
no apoptosis, suggesting that a focal micro-environment is required to initiate 
apoptosis 73. In our study cultured Cy/+ cells had a low apoptotic rate, suggesting that 
Cy/+ cells were not intrinsically pro-apoptotic and further supports the hypothesis that 
in polycystic kidneys external pro-apoptotic signals are required to induce apoptosis.  
  
In the present study, we assessed apoptosis by several methods: western blot of 
caspase 3, the converge point of intrinsic mitochondrial pathway and extrinsic death 
receptor-mediated pathway; annexin V/PI FACS analysis, which detects both early 
and late apoptotic cells; the APOPercentage Apoptosis Assay, which only measures 
early apoptotic cells. All three methods showed that everolimus had no effect on 
apoptosis induction in Cy/+ tubular epithelial cells. It has been shown that mTOR 
inhibitors within the clinical concentration did not induce apoptosis in several cancer 
cells and non-cancer cells, suggesting the function of mTOR inhibitors rather as 
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cytostatic effectors by arresting cells at G1 phase than as apoptosis inducers 107, 108, 
112.  Indeed in our animal models, everolimus or rapamycin treatment did not induce 
the shrinking of cystic kidney but only stopped its growth 62, 80. 
 
To elucidate the mechanisms of ADPKD cyst formation in vitro, a 3D culture of 
primary renal epithelial cells was established with primary cells isolated from +/+ and 
Cy/+ Han:SPRD rats. Classic in vitro cystogenesis involves in three major steps: 1) 
aggregates formation, 2) hollow lumen formation by vesicle exocytosis and luminal 
cell apoptosis, 3) cyst expansion 113. In our study primary Cy/+ and +/+ TECs were 
collected at day 1 and were cultured in suspension in plates pre-coated with 1% agar 
to prevent adhesion, leading to the formation of cell aggregates in 48 h. However, the 
majority of aggregates contained no lumen; rarely aggregates with small lumen were 
observed. The efficiency of luminal aggregate formation in our primary TECs was 
lower than the dog renal epithelial cell line MDCK cells, probably due to the high 
resistance of primary cells to cell apoptosis and lower capacity to form polarized cell 
sheets in the absence of other cell types relative to MDCK cells. Inhibition of 
apoptosis prevented cyst formation in the 3D cultured MDCK cells 114 and the low 
rate of apoptosis found in Cy/+ may explain the absence of lumen in our model. In a 
previous study by Pey et al. cystic structures that were formed few hours after plating 
primary cells from Cy/+ Han:SPRD rats, markers were not showed to prove luminal 
formation 115.  
 
We showed that Cy/+ cells formed significantly larger aggregates than +/+ cells. Cy/+ 
cells demonstrated a wider range of aggregate sizes than +/+ cells but with a similar 
lower limit, which suggested there was a diversity in proliferation rates of Cy/+ cells 
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spanning from normal to higher than normal values. Treatment of Cy/+ cells with 1-
100 nM everolimus significantly reduced aggregate diameter, which was tightly 
associated with the dose-dependant reduction of cell proliferation rate and mTOR 
activity by everolimus in monolayer Cy/+ cell culture. Interestingly, the lower limit of 
Cy/+ aggregate size stayed unchanged suggesting that everolimus treatment 
selectively affected Cy/+ cells with higher than normal proliferation rates. Thus, 
inhibitors of mTOR might reduce renal cyst formation and growth by suppressing 
mTOR-mediated cell proliferation. 
 
In conclusion, 0.1 nM could be the lowest biological dose for everolimus to inhibit 
Cy/+ TEC growth. A low level of everolimus selectively reduced Cy/+ aggregate size, 
which is paralleled with the inhibition of mTOR pathway, but not with the induction of 
apoptosis.  
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Legends 
 
Figure 1. 
Viable +/+ (open circles) and Cy/+ (closed circles) TECs were assessed by 
colorimetric MTS assay from 0 h (day 1) to 48 h (day 3). All experiments were 
performed in triplicates, bar indicate mean (SEM). Results were reported as OD 
value. 
 
Figure 2. 
Cy/+ TECs were treated with various concentrations of everolimus (0.01 to 100 nM) 
for two days. At day3 (A) MTS and (B) BrdU assay were used to determine viable cell 
number and DNA synthesis of Cy/+ TECs, respectively. All experiments were 
performed in triplicates, bar indicate mean (SEM). Results were reported as OD 
value. (p<0.0001 versus everolimus 0 nM, double asterisk)  
 
Figure 3.   
Cy/+ TECs were treated with various concentrations of everolimus (0.01 to 100 nM) 
for 1 day for apoptosis analysis at day 3. (A) Whole cell lysate was subjected to 
Western analysis to exam the expression of full-length (32 kD) and cleaved (17 kD) 
caspase-3. Western blot of actin serves as internal control. Representative blot is 
shown. (B) Representative FACS analysis of annexin V and PI staining of Cy/+ TECs. 
(C) Cy/+ TECs were stained by APOPercentage kit. Apoptotic cells are stained red. 
(D) Quantification of results from APOPercentage staining as OD value. 1 mM H2O2 
treated TECs served as positive control. Representative data are shown.  Error bar 
indicated SEM of triplicate culture.  
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Figure 4.   
Cy/+ TECs were treated with various concentrations of everolimus (0.01 to 100 nM) 
for 1 day. Cell lysates were collected at day 3. (A) Western analysis of total, p2481 
and p2448 mTOR are shown. (B) Western analysis of total, p389, p421/424 S6 
kinase and p235/236 S6 are shown. Western blot of actin serves as internal control. 
Representative blot is shown. 
  
Figure 5.   
(A) Representative images of +/+ and Cy/+ TEC aggregates grown in collagen type I 
(0.15 g/L) gel. (B) Double staining for cells’ outline (F-actin; green) and nuclei (blue) 
indicate absence of lumen in Het aggregates. Bar 5 µm. (C) The diameter of Cy/+ 
and +/+ TEC aggregates after 48 hours of growth on non-adhesive plates in the 
presence of 1 nM or 100 nM everolimus or solvent (DMSO). Everolimus significantly 
(p<0.0001, double asterisk) reduced aggregate size of Cy/+ but not +/+ TECs. (D) 
Representative phase-contrast images of Cy/+ and +/+ TEC suspension cultures 
described in (C). Bar 30 µm. 
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Figure 3 
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Figure 4 
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Conclusion and discussion of current work   
Because of the important role of mTOR signaling in cell proliferation and 
growth, mTOR inhibitors such as sirolimus and everolimus have been used to treat 
cancer patients. Our findings demonstrate that everolimus retarded cyst growth and 
preserved renal function, which was associated with decreased cell proliferation in 
renal tubules in Cy/+ Han:SPRD rats. Together with previous study of sirolimus, we 
showed a class effect of mTOR inhibitors on disease progression in polycystic kidney 
disease.   
The effect of mTOR inhibitor withdrawal has not been studied so far. In the 
second study, we showed that everolimus pulse treatment (everolimus withdrawal) 
and everolimus continuous treatment had same anti-cystic and reno protective 
effects, although a partial reactivation of S6 kinase and recovery of cell proliferation 
were observed 7 weeks after cessation of everolimus treatment.  
Recent studies show that  the timing of cystogenesis is critical for disease 
progression in PKD 6, 18. Inactivation of these genes in adult mice only causes a 
slower progressive cystic disease. Our current study showed that the retardation of 
cyst growth by mTOR inhibitor everolimus at an early age (4-9 weeks) in Cy/+ rats 
led to a non-cystic/less-cystic hypertrophic phenotype seven weeks after everolimus 
withdrawal. These findings therefore suggest that blocking cystogenesis in the early 
time could change the course of disease progression in PKD.  
In our third study, we established an in vitro primary cell culture model for PKD 
by showing a hyper-proliferative renal tubular epithelial cells derived from Cy/+ rats. 
We demonstrated that 0.1 nM was the lowest biological dosage of everolimus to 
inhibit cell proliferation, which was tightly linked to mTOR/S6 kinase activity.  We 
showed that the level of apoptosis was low in Cy/+ cells in vitro and everolimus had 
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no effect on apoptosis in Cy/+ cells.  mTORC2 plays an important role in cell survival 
and provides resistance to apoptosis 92.  Indeed, we showed in the second study that 
the activity of mTORC2 was up-regulated in Cy/+ rats and resistant to continuous 
everolimus treatment.  This is because that suppression of mTORC2 activity required 
a very high level of mTOR inhibitor (µM) 92. An in vivo mouse study reported that 
rapamycin reversed cyst growth and enhanced apoptosis in cystic kidneys 45. 
However the blood concentration of rapamycin in this study was not known.  The 
sensitivity of mTORC2 depends on the intracellular phosphatidic acid (PA) level, 
which is often up-regulated in tumour cells and binds/stabilizes mTOR complex, 
thereby rendering the resistance of mTOR complex to everolimus/rapamycin. 
Therefore combination therapy of PA inhibitor and everolimus could be tested in vitro 
and in adult Cy/+ rats. 
Model of cyst formation and expansion 
After literature study of research papers and review articles published in the 
field of PKD in recent three years, we summarized the most important factors for cyst 
formation, expansion and maintainence of cystic phenotype (Table 1). We can see 
the importance of disrupted PCP, defect cell migration, and high proliferation/ 
apoptosis background as driving forces to initiate cyst formation. The disrupted PCP 
and cell migration are caused by germline mutation or inflammation mediated 
reduction of PKD protein dosage in primary cilia or cell adhesion junctions. Once a 
cystic phenotype is generated, the focal cyst may produce mitogenic and 
inflammatory factors to expand itself and transform its surrounding tubule into a 
cystic phenotype.  
 
Table 1 Important factors for cyst formation and expansion 
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 Factors Causes 
Reduced PKD 
protein dosage 
• Germline mutation  
• Defect of intracellular PKD 
protein trafficking caused by 
inflammatory factors like TNF-a 
Disrupted PCP 
and cell migration
• Reduced PKD protein dosage 
leading to impaired cilia  
• Impaired cell-cell adhension and 
cell-matrix adhension 
Cyst formation 
High proliferation 
and apoptosis 
background 
• In kidney developmental period  
• Local infection  
• Local injury 
 
 
Cystic cell 
phenotype 
• Disrupted epithelial cell polarity  
• Secretary phenotype  
• Proliferative phenotype  
• Activated inflammatory factors ( NF-kb and TNF-a) 
 
 
 Factors Causes 
Cyst expansion High secretion • Loss of cell polarity 
• Defect of calcium/cAMP signals  
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High proliferation • Loss of cell polarity 
• Defect of calcium/cAMP signals 
Enhanced 
inflammation 
• Active NFkb in cystic epithelial 
cells induced local inflammation 
Enhanced 
apoptosis 
• Local inflammation induced 
noncystic cell apoptosis 
 
Perspective and outlook 
Timing of treatment and inhibition of PCP pathway in ADPKD 
The focus of PKD research is shifting from primary cilium to the timing of 
cystogenesis and PCP in PKD in recent years. With our rat PKD model and the tool 
of everolimus, we could study the effect of treatment time on ADPKD based on the 
timing of cystogenesis and cyst development. Further studies with everolimus may 
involve three treatment time points (postnatal period, developing period, adult period), 
which would be of great relevance to clinic situation.    
Seven years ago, before discovery of PCP issue in PKD, the effects of PPAR-
gamma agonist has been tested in Pkd1 knockout mice 116. Maternally administered 
pioglitazone, a PPAR-gamma agonist, improved embryonic survival of mutant mice 
and reduced the extent of renal cystogenesis, however the mechanism is unknown. It 
has been shown that PPARγ agonists repress the Wnt/β-catenin signaling 117. 
Therefore we hypothesize that PPARγ agonists inhibit cystogensis via suppressing 
Wnt/β-catenin signals and thereby rescue the impaired PCP in PKD. With the 
collaboration with our Chinese partners, who developed several new PPARγ agonists, 
we are able to test the effect of PPARγ agonists in our rat model of ADPKD. 
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Issue of inflammation in ADPKD 
Very recently, the role of immune system/inflammation as a non-genetic factor 
(third hit) has been emphasized by several top scientists in this field of PKD. With our 
everolimus withdrawal model, we can study whether inflammatory/environmental 
factors such as TNF-α can accelerate disease progression after everolimus 
withdrawal. In addition, in a very recent study, nuclear factor-kB (NF-kB) has been 
found to be up-regulated in pkd1 deficient cells and cystic cells 31.  NFkB is a 
transcription factor thought to play an important role in the onset of inflammation. It 
would be interesting to see whether inhibition of NFkB retards disease progression in 
Cy/+ rats by preventing the recruitment of inflammatory cells to cystic tissues. 
Sirolimus and everolimus were initially used as immunosuppressants and can inhibit 
the activity of macrophages, dendritic cells and conventional T cells. A recent study 
has also shown that mTOR deficiency leads to induction of regulatory T cells 118. 
Therefore, we can not exclude that the inhibition of disease progression by 
everolimus in Cy/+ rats is partly mediated by inhibition of immune system or induction 
of regulatory T cells.  
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